Oral composition of celecoxib for treating pain

A stable oral liquid composition of celecoxib with solubilizers and glycerides enhances absorption, addressing the solubility and bioavailability issues of celecoxib, resulting in faster pain relief.

CN119055585APending Publication Date: 2024-12-03DR REDDYS LAB LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411206507.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2016-05-27
Filing Date
2017-05-26
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Celecoxib, a hydrophobic and highly permeable drug, has limited bioavailability and delayed onset of pharmacological action due to poor solubility and absorption in the gastrointestinal tract, necessitating compositions that provide rapid pain relief.

Method used

A stable oral liquid pharmaceutical composition comprising celecoxib, solubilizers, medium chain glycerides, and polar solvents that enhance solubility and dispersion in the gastrointestinal tract, preventing precipitation in gastric fluid and ensuring rapid absorption.

Benefits of technology

The composition provides faster pain relief by achieving rapid absorption and increased bioavailability of celecoxib, with pharmacokinetic parameters indicating improved AUC and reduced time to peak plasma concentration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005019174580000012
    Figure BDA0005019174580000012
  • Figure BDA0005019174580000451
    Figure BDA0005019174580000451
  • Figure BDA0005019174580000461
    Figure BDA0005019174580000461
Patent Text Reader

Abstract

The present invention relates to an oral composition of celecoxib for the treatment of pain, in particular a stable oral liquid pharmaceutical composition of celecoxib or a pharmaceutically acceptable salt thereof. Celecoxib present in a composition as described herein does not exhibit any precipitation for at least 60 minutes when subjected to fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37 DEG C + / -0.5 DEG C under agitation at a speed of 50 rpm. The present application also relates to methods of making the celecoxib compositions and methods of using the celecoxib compositions.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of Chinese patent application No. 201780046265.7, filed on May 26, 2017, entitled “Celecoxib oral composition for treating pain”.

[0002] Related Applications

[0003] This application claims priority to U.S. Provisional Patent Application No. 62 / 342,874, filed May 27, 2016, the entire disclosure of which is incorporated herein by reference. Technical Field

[0004] The present application relates to a pharmaceutical composition, in particular to an oral celecoxib composition for treating pain and its application. Background Art

[0005] Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat acute pain, inflammatory pain, visceral pain, breakthrough pain, nociceptive pain, neuropathic pain, dysmenorrhea, postoperative pain, acute postpartum pain, postoperative pain management, chronic pain in osteoarthritis, rheumatoid arthritis, and pain from other diseases and causes.

[0006] Celecoxib is sold in the United States under the trade name Approved as an oral capsule and used to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain, chronic pain, primary dysmenorrhea, and familial adenomatous polyposis. Available strengths are 50 mg, 100 mg, 200 mg, and 400 mg.

[0007] Celecoxib is described in US Pat. No. 5,466,823 assigned to Searle, which describes a class of 1,5-diarylpyrazoles and their salts and methods of making these compounds.

[0008] Celecoxib is chemically named 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, which is a diaryl-substituted pyrazole. The empirical formula is C 17 H 14 F3N3O2S, molecular weight is 381.38; chemical structure is as follows:

[0009]

[0010] U.S. Patent No. 5,466,823 contains general reference to formulations for administering 1,5-diarylpyrazoles, including oral administration dosage forms such as tablets and capsules.

[0011] US Patent No. 5,760,068 describes a class of 1,5-diarylpyrazole compounds, including celecoxib, which are selective inhibitors of cyclooxygenase-2 and can be administered to treat conditions and disorders such as pathological conditions associated with rheumatoid arthritis and osteoarthritis.

[0012] Celecoxib is a hydrophobic and highly permeable drug belonging to Class II of the biopharmaceutics classification system. Celecoxib is a substantially water-insoluble neutral molecule, which results in higher absorption variability and therefore has limited bioavailability after oral administration. It also has pre-systemic metabolism.

[0013] Celecoxib has an aqueous solubility of about 5 μg / ml between 5°C and 40°C, which is pH-independent at pH<9. When administered orally, for example in the form of capsules, celecoxib is not easily dissolved and dispersed for rapid absorption in the gastrointestinal tract. Oral administration is associated with a delayed onset of the desired pharmacological action. It is known that celecoxib takes about 3 hours to reach peak plasma concentration when administered orally, and therefore has a delayed onset after administration. In addition, the intake of food further affects drug absorption. However, in the case of migraine, surgical pain, injury, pain caused by kidney stones, and arthritis, acute pain requires immediate or faster pain relief.

[0014] Thus, there remains an unmet need in the art for compositions of celecoxib or a pharmaceutically acceptable salt thereof that provide more rapid pain relief. Summary of the invention

[0015] The present application provides compositions comprising celecoxib or a pharmaceutically acceptable salt thereof and methods for administering such compositions, which can be easily dissolved and / or dispersed for rapid absorption in the gastrointestinal tract, thereby providing faster pain relief.

[0016] Some embodiments disclosed herein provide a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C when measured at 60 minutes under stirring at a speed of 50 rpm.

[0017] In some embodiments, the composition is substantially free of a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer. In some embodiments, the at least one solubilizing agent is polyethoxylated castor oil (KOLLIPHOR Commercially available), lauryl macrogolglycerides (lauryl macrogolglycerides) ( 44 / 14 commercially available), or a combination thereof.

[0018] In some embodiments, the at least one medium chain glyceride is tricaprylin / tricaprin (in 300 commercially available), monocaprylic acid glyceryl ( In some embodiments, the at least one polar solvent is selected from the group consisting of propylene glycol, polyethylene glycol with a molecular weight of 400 to 1000, glycerol, C2 to C8 monohydric alcohols and polyhydric alcohols (e.g., ethanol), C7 to C8 in a linear or branched configuration. 18 Alcohol, water, and combinations thereof.

[0019] In some embodiments, the therapeutically effective amount of celecoxib is about 1 wt % to about 80 wt % of celecoxib based on the total weight of the composition. In some embodiments, the at least one solubilizing agent is present in an amount of about 10 wt % to about 70 wt % of the total weight of the composition.

[0020] In some embodiments, the weight ratio of the at least one solubilizing agent to celecoxib is about 4.0:1.0 to about 20:1.0. In some embodiments, the at least one polar solvent is present in an amount of about 20% to about 80% by weight of the total weight of the composition. In some embodiments, the weight ratio of the at least one solubilizing agent to the at least one polar solvent is about 0.60:1.00 to about 1.8:1.00.

[0021] In some embodiments, the at least one medium chain glyceride is present in an amount of about 5% to about 75% by weight of the total weight of the composition. In some embodiments, the average oil droplet size of the composition is no greater than 500 nm when tested in 250 ml fasting state simulated gastric fluid (FaSSGF) at pH 2.0 and 37°C ± 0.5°C under stirring at 50 rpm.

[0022] In some embodiments, the viscosity of the composition is from about 20 cps to about 1000 cps. In some embodiments, the density of the composition is about 0.8 gm / cm 3 to about 2gm / cm 3In some embodiments, the composition has a light transmittance of at least 40%. In some embodiments, the composition has a pH of about 3 to about 7.

[0023] In some embodiments, the therapeutically effective amount of celecoxib is greater than a conventional celecoxib composition (e.g., 400 mg oral capsule) is at least about 40%. In some embodiments, the therapeutically effective amount of celecoxib is about 240 mg. In some embodiments, the therapeutically effective amount of celecoxib is at least about 40% less than a conventional celecoxib composition (e.g., 400 mg oral capsule) is at least about 55% less. In some embodiments, the therapeutically effective amount of celecoxib is about 180 mg. In some embodiments, the therapeutically effective amount of celecoxib is about 180 mg less than a conventional celecoxib composition (e.g., 400 mg oral capsule) by at least about 70%.

[0024] In some embodiments, the therapeutically effective amount of celecoxib is about 120 mg. In some embodiments, the stable oral liquid pharmaceutical composition provides at least one of the following pharmacokinetic parameters when orally administered to a human subject under fasting conditions:

[0025] AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0026] AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0027] AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0028] AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0029] AUC of at least about 2000 ng.h / mL (0-t) ;

[0030] AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0031] The time delay (T lag ).

[0032] In some embodiments, the stable oral liquid pharmaceutical composition comprises: a) a therapeutically effective amount of celecoxib; b) at least one pharmaceutically acceptable excipient; c) at least one solubilizing agent in an amount of about 35% w / w to about 45% w / w; and d) at least one polar solvent in an amount of about 25% w / w to about 42% w / w, wherein the solubilizing agent and the polar solvent are present in a weight ratio of about 0.60:1 to about 1.8:1; and wherein the stable oral liquid pharmaceutical composition has a viscosity of about 20 cps to about 1000 cps and a density of about 0.8 gm / cm 3 to about 2gm / cm 3 .

[0033] Some embodiments disclosed herein provide a stable oral liquid pharmaceutical composition comprising about 100 mg to 250 mg of celecoxib, at least one pharmaceutically acceptable excipient, at least one solubilizer, at least one medium chain glyceride, and at least one polar solvent, wherein, when tested in a USP Type 2 apparatus with a sinker at 50 rpm and 37° C., in 900 ml of 0.01 N HCl with 0.5% sodium lauryl sulfate, the composition: a) releases not less than about 70% of the celecoxib over a period of 10 minutes; or b) releases not less than about 80% of the celecoxib over a period of 15 minutes.

[0034] In some embodiments, the composition is substantially free of a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer. In some embodiments, the at least one solubilizing agent is polyethoxylated castor oil (KOLLIPHOR Commercially available), lauric acid macrogol glyceride ( 44 / 14 commercially available), or a combination thereof. In some embodiments, the at least one medium chain glyceride is tricaprylin / tricaprin (commercially available as 300 commercially available), monocaprylic acid glyceryl ( MCM C8 is commercially available), or a combination thereof.

[0035] In some embodiments, the at least one polar solvent is selected from the group consisting of propylene glycol, polyethylene glycol with a molecular weight of 400 to 1000, glycerol, C2 to C8 monohydric alcohols and polyhydric alcohols (e.g., ethanol), C7 to C8 in a linear or branched configuration. 18 Alcohol, water, and combinations thereof.

[0036] In some embodiments, the therapeutically effective amount of celecoxib is about 1% to about 80% by weight of celecoxib accounting for the total weight of the composition. In some embodiments, the at least one solubilizing agent is present in an amount of about 10% to about 70% by weight of the total weight of the composition. In some embodiments, the weight ratio of the at least one solubilizing agent to celecoxib is about 4.0:1.0 to about 20:1.0.

[0037] In some embodiments, the at least one polar solvent is present in an amount of about 20 wt % to about 80 wt % of the total weight of the composition. In some embodiments, the weight ratio of the at least one solubilizing agent to the at least one polar solvent is about 0.60:1.00 to about 1.8:1.00.

[0038] In some embodiments, the at least one medium chain glyceride is present in an amount of about 5% to about 75% by weight of the total weight of the composition. In some embodiments, the average oil droplet size of the composition is no greater than 500 nm when tested in 250 ml fasting state simulated gastric fluid (FaSSGF) at pH 2.0 and 37°C ± 0.5°C under stirring at 50 rpm.

[0039] In some embodiments, the viscosity of the composition is from about 20 cps to about 1000 cps. In some embodiments, the density of the composition is about 0.8 gm / cm 3 to about 2gm / cm 3 In some embodiments, the composition has a light transmittance of at least 40%. In some embodiments, the composition has a pH of about 3 to about 7.

[0040] In some embodiments, the therapeutically effective amount of celecoxib is greater than a conventional celecoxib composition (e.g., 400 mg oral capsule) is at least about 40%. In some embodiments, the therapeutically effective amount of celecoxib is about 240 mg. In some embodiments, the therapeutically effective amount of celecoxib is at least about 40% less than a conventional celecoxib composition (e.g., 400 mg oral capsule) is at least about 55% less. In some embodiments, the therapeutically effective amount of celecoxib is about 180 mg. In some embodiments, the therapeutically effective amount of celecoxib is about 180 mg less than a conventional celecoxib composition (e.g., 400 mg oral capsule) is at least about 70% less. In some embodiments, the therapeutically effective amount of celecoxib is about 120 mg.

[0041] In some embodiments, the stable oral liquid pharmaceutical composition, when orally administered to a human subject under fasting conditions, provides at least one of the following pharmacokinetic parameters:

[0042] AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0043] AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0044] AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0045] AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0046] AUC of at least about 2000 ng.h / mL (0-t) ;

[0047] AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0048] The time delay (T lag ).

[0049] In some embodiments, the stable oral liquid pharmaceutical composition comprises: a) a therapeutically effective amount of celecoxib; b) at least one pharmaceutically acceptable excipient; c) at least one solubilizing agent in an amount of about 35% w / w to about 45% w / w; and d) at least one polar solvent in an amount of about 25% w / w to about 42% w / w, wherein the solubilizing agent and the polar solvent are present in a weight ratio of about 0.60:1 to about 1.8:1; and wherein the stable oral liquid pharmaceutical composition has a viscosity of about 20 cps to about 1000 cps and a density of about 0.8 gm / cm 3 to about 2gm / cm 3 .

[0050] Some embodiments disclosed herein provide methods for treating pain in a human subject, the methods comprising administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer in an amount from about 35% w / w to about 45% w / w, at least one polar solvent in an amount from about 25% w / w to about 42% w / w, at least one medium chain glyceride, and at least one pharmaceutically acceptable excipient, wherein the stable oral liquid pharmaceutical composition is substantially free of a precipitation inhibitor.

[0051] In some embodiments, the pain is associated with migraine. In some embodiments, the therapeutically effective amount of celecoxib is sufficient to eliminate the pain of the individual within 2 hours after administration of the stable oral liquid pharmaceutical composition. In some embodiments, the therapeutically effective amount of celecoxib is sufficient to cause partial pain relief in the individual within 2 hours after administration of the stable oral liquid pharmaceutical composition. In some embodiments, administration of the stable oral liquid pharmaceutical composition results in at least 25% of the treated human individuals eliminating pain 2 hours after administration. In some embodiments, administration of the stable oral liquid pharmaceutical composition results in at least 45% of the treated human individuals partially relieving pain 2 hours after administration.

[0052] In some embodiments, the administration of the stable oral liquid pharmaceutical composition causes the percentage of the treated human individual who eliminates pain 2 hours after administration to increase by at least 40% compared with the percentage of the human individual treated with placebo. In some embodiments, the administration of the stable oral liquid pharmaceutical composition causes the percentage of the treated human individual who partially relieves pain 2 hours after administration to increase by at least 10% compared with the percentage of the human individual treated with placebo. In some embodiments, the administration of the stable oral liquid pharmaceutical composition causes the percentage of the treated human individual who eliminates pain 2 hours after administration to increase by at least 10% compared with the percentage of the human individual treated with commercially available migraine therapeutic agents (e.g., VIOXX 25 (25mg), VIOXX 50 (50mg) and CAMBIA 50 (50mg)). In some embodiments, administration of the stable oral liquid pharmaceutical composition results in at least a 10% increase in the percentage of treated human subjects with partial pain relief 2 hours after administration compared to the percentage of human subjects treated with commercially available migraine treatments (e.g., VIOXX 25 (25 mg), VIOXX 50 (50 mg), and CAMBIA 50 (50 mg)).

[0053] In some embodiments disclosed herein, a method for providing pain relief to a human subject suffering from pain comprises administering to the subject a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib. In some embodiments disclosed herein, a method for providing pain relief to a human subject suffering from pain comprises administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib.

[0054] In some embodiments disclosed herein, a method for providing pain relief to a human subject suffering from pain 2 hours after administration comprises administering to the subject a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib. In some embodiments disclosed herein, a method for providing pain relief to a human subject suffering from pain 2 hours after administration comprises administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib.

[0055] In some embodiments, a method for providing partial pain relief to a human subject suffering from pain in less than about 2 hours after administration comprises administering to the subject a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib. In some embodiments, a method for providing partial pain relief to a human subject suffering from pain in less than about 2 hours after administration comprises administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib.

[0056] In some embodiments, a method for providing partial pain relief to a human subject with pain in less than about 2 hours after administration comprises administering to the subject a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib, wherein the partial pain relief lasts for at least about 4 hours. In some embodiments, a method for providing partial pain relief to a human subject with pain in less than about 2 hours after administration comprises administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, wherein the partial pain relief lasts for at least about 4 hours.

[0057] In some embodiments, a method for providing partial pain relief to a human subject with pain less than about 2 hours after administration comprises administering to the subject a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib, wherein the partial pain relief is that the pain intensity reported by the human subject with pain is ≥1 level lower than the rating before administration according to a 4-level numeric rating scale for pain ranging from 0 (no pain) to 3 (severe pain). In some embodiments, a method for providing partial pain relief to a human subject with pain less than about 2 hours after administration comprises administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, wherein the partial pain relief is that the pain intensity reported by the human subject with pain is ≥1 level lower than the rating before administration according to a numeric rating scale for pain ranging from 0 (no pain) to 3 (severe pain).

[0058] In some embodiments disclosed herein, a method for providing pain relief to a human subject suffering from pain comprises administering to the subject a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib, wherein the pain relief is maintained for at least about 2 hours to about 24 hours. In some embodiments disclosed herein, a method for providing pain relief to a human subject suffering from pain comprises administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, wherein the pain relief is maintained for at least about 2 hours to about 24 hours.

[0059] In some embodiments, a method for reducing the most bothersome symptom in a human subject suffering from migraine comprises administering to the subject a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib, wherein the most bothersome symptom is reduced within about 2 hours after administration of the composition. In some embodiments, a method for reducing the most bothersome symptom in a human subject suffering from migraine comprises administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, wherein the most bothersome symptom is reduced within about 2 hours after administration of the composition.

[0060] In one aspect of the above embodiment, the method maintains the elimination of the most bothersome symptom associated with migraine for at least about 2 hours to about 24 hours. In some embodiments, the method for reducing the most bothersome symptom in a human subject suffering from migraine comprises administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, wherein the method maintains the elimination of the most bothersome symptom associated with migraine for at least about 2 hours to about 24 hours.

[0061] Some embodiments disclosed herein provide for the use of a stable oral liquid pharmaceutical composition disclosed in any embodiment of the present application for treating pain in an individual. In some embodiments, the stable oral liquid pharmaceutical composition comprises a therapeutically effective amount of celecoxib, at least one solubilizing agent in an amount of about 35% w / w to about 45% w / w, at least one polar solvent in an amount of about 25% w / w to about 42% w / w, at least one medium chain glyceride, and at least one pharmaceutically acceptable excipient, wherein the stable oral liquid pharmaceutical composition is substantially free of a precipitation inhibitor. In some embodiments, the pain is associated with migraine.

[0062] In some embodiments, the therapeutically effective amount of celecoxib is sufficient to eliminate pain in the individual within 2 hours after administration of the stable oral liquid pharmaceutical composition. In some embodiments, the therapeutically effective amount of celecoxib is sufficient to cause partial pain relief in the individual within 2 hours after administration of the stable oral liquid pharmaceutical composition.

[0063] In some embodiments, administration of the stable oral liquid pharmaceutical composition results in at least 25% of the treated human subjects being pain free at 2 hours. In some embodiments, administration of the stable oral liquid pharmaceutical composition results in at least 45% of the treated human subjects being partially pain relieved at 2 hours. In some embodiments, administration of the stable oral liquid pharmaceutical composition results in an increase of at least 40% in the percentage of treated human subjects with pain free at 2 hours compared to the percentage of human subjects treated with a placebo. In some embodiments, administration of the stable oral liquid pharmaceutical composition results in an increase of at least 10% in the percentage of treated human subjects with partial pain relief at 2 hours compared to the percentage of human subjects treated with a placebo.

[0064] In some embodiments, administration of the stable oral liquid pharmaceutical composition results in an increase of at least 10% in the percentage of human subjects treated with pain relief at 2 hours compared to the percentage of human subjects treated with commercially available migraine therapeutics (e.g., VIOXX 25 (25 mg), VIOXX 50 (50 mg), and CAMBIA 50 (50 mg)). In some embodiments, administration of the stable oral liquid pharmaceutical composition results in an increase of at least 10% in the percentage of human subjects treated with partial pain relief at 2 hours compared to the percentage of human subjects treated with commercially available migraine therapeutics (e.g., VIOXX 25 (25 mg), VIOXX 50 (50 mg), and CAMBIA 50 (50 mg)).

[0065] Some embodiments disclosed herein provide a stable oral liquid pharmaceutical composition of celecoxib, the composition comprising (i) a therapeutically effective amount of celecoxib, at least one solubilizing agent, at least one medium chain glyceride; and (ii) a polar solvent comprising a mixture of ethanol and glycerol; wherein the composition falls within the range of Figure 1 In the shaded area of ​​the phase diagram shown, wherein the boundary of the stable composition is defined by the shaded area or by the area between the connecting lines between the six points (a, b, c, d, e and f), wherein the composition comprises about 1% w / w to about 80% w / w of celecoxib and corresponds to the following base composition: weight percentages of ethanol:glycerol: for a, 0.200:0.024:0.712, for b, 0.200:0.376:0.360, for c, 0.200:0.400:0.336, for d, 0.536:0.400:0.000, for e, 0.900:0.036:0.00, and for f, 0.900:0.00:0.036.

[0066] In some embodiments, the composition does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at pH 2.0 and temperature 37°C ± 0.5°C when measured at 60 minutes under stirring at a speed of 50 rpm. In some embodiments, the composition is substantially free of a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer. In some embodiments, the at least one solubilizing agent is polyethoxylated castor oil (KOLLIPHOR Commercially available), lauric acid macrogol glyceride ( 44 / 14 commercially available), or a combination thereof. In some embodiments, the at least one medium chain glyceride is tricaprylin / tricaprin (commercially available as 300 commercially available), monocaprylic acid glyceryl ( MCMC8 is commercially available), or a combination thereof.

[0067] In some embodiments, the at least one polar solvent is selected from the group consisting of propylene glycol, polyethylene glycol with a molecular weight of 400 to 1000, glycerol, C2 to C8 monohydric alcohols and polyhydric alcohols (e.g., ethanol), C7 to C8 in a linear or branched configuration. 18 Alcohol, water, and combinations thereof.

[0068] In some embodiments, the therapeutically effective amount of celecoxib is about 1 wt % to about 80 wt % of celecoxib based on the total weight of the composition. In some embodiments, the at least one solubilizing agent is present in an amount of about 10 wt % to about 70 wt % of the total weight of the composition.

[0069] In some embodiments, the weight ratio of the at least one solubilizing agent to celecoxib is about 4.0:1.0 to about 20:1.0. In some embodiments, the at least one polar solvent is present in an amount of about 20 wt % to about 80 wt % of the total weight of the composition.

[0070] In some embodiments, the at least one solubilizing agent is present in an amount of about 10% by weight to about 70% by weight of the total weight of the composition. In some embodiments, the weight ratio of the at least one solubilizing agent to celecoxib is about 4.0:1.0 to about 20:1.0. In some embodiments, the at least one polar solvent is present in an amount of about 20% by weight to about 80% by weight of the total weight of the composition. In some embodiments, the weight ratio of the at least one solubilizing agent to the at least one polar solvent is about 0.60:1.00 to about 1.8:1.00.

[0071] In some embodiments, the at least one medium chain glyceride is present in an amount of about 5% to about 75% by weight of the total weight of the composition. In some embodiments, when tested in 250 ml of fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C under stirring at a speed of 50 rpm, the average oil droplet size of the composition is no more than 500 nm. In some embodiments, the viscosity of the composition is from about 20 cps to about 1000 cps. In some embodiments, the density of the composition is about 0.8 gm / cm 3 to about 2gm / cm 3 In some embodiments, the composition has a light transmittance of at least 40%. In some embodiments, the composition has a pH of about 3 to about 7.

[0072] In some embodiments, the therapeutically effective amount of celecoxib is greater than a conventional celecoxib composition (e.g., 400 mg oral capsule) is at least about 40%. In some embodiments, the therapeutically effective amount of celecoxib is about 240 mg. In some embodiments, the therapeutically effective amount of celecoxib is at least about 40% less than a conventional celecoxib composition (e.g., 400 mg oral capsule) is at least about 55% less. In some embodiments, the therapeutically effective amount of celecoxib is about 180 mg. In some embodiments, the therapeutically effective amount of celecoxib is about 180 mg less than a conventional celecoxib composition (e.g., 400 mg oral capsule) is at least about 70% less. In some embodiments, the therapeutically effective amount of celecoxib is about 120 mg.

[0073] In some embodiments, the stable oral liquid pharmaceutical composition, when orally administered to a human subject under fasting conditions, provides at least one of the following pharmacokinetic parameters:

[0074] AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0075] AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0076] AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0077] AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0078] AUC of at least about 2000 ng.h / mL (0-t) ;

[0079] AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0080] T not exceeding 8 minutes lag .

[0081] In some embodiments, the stable oral liquid pharmaceutical composition comprises: a) a therapeutically effective amount of celecoxib; b) at least one pharmaceutically acceptable excipient; c) at least one solubilizing agent in an amount of about 35% w / w to about 45% w / w; and d) at least one polar solvent in an amount of about 25% w / w to about 42% w / w, wherein the solubilizing agent and the polar solvent are present in a weight ratio of about 0.60:1 to about 1.8:1; and wherein the stable oral liquid pharmaceutical composition has a viscosity of about 20 cps to about 1000 cps and a density of about 0.8 gm / cm 3 to about 2gm / cm 3 .

[0082] Some embodiments disclosed herein provide methods for treating pain in a human subject, the methods comprising administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one polar solvent, at least one medium chain glyceride, and at least one pharmaceutically acceptable excipient, wherein the stable oral liquid pharmaceutical composition is substantially free of a precipitation inhibitor, wherein the therapeutically effective amount of celecoxib is sufficient to provide relief from pain in the subject for at least 24 hours after administration of the stable oral liquid pharmaceutical composition.

[0083] In some embodiments, the stable oral liquid pharmaceutical composition comprises a therapeutically effective amount of celecoxib, at least one solubilizer in an amount from about 35% w / w to about 45% w / w, at least one polar solvent in an amount from about 25% w / w to about 42% w / w, at least one medium chain glyceride, and at least one pharmaceutically acceptable excipient, wherein the stable oral liquid pharmaceutical composition is substantially free of a precipitation inhibitor.

[0084] In some embodiments, the pain is associated with migraine. In some embodiments, the therapeutically effective amount of celecoxib is sufficient to eliminate pain in the individual within 2 hours after administration of the stable oral liquid pharmaceutical composition. In some embodiments, the therapeutically effective amount of celecoxib is sufficient to cause partial pain relief in the individual within 2 hours after administration of the stable oral liquid pharmaceutical composition. In some embodiments, administration of the stable oral liquid pharmaceutical composition results in at least 25% of the treated human individuals eliminating pain for at least 24 hours after treatment. In some embodiments, administration of the stable oral liquid pharmaceutical composition results in at least 45% of the treated human individuals eliminating pain for at least 24 hours after treatment. In some embodiments, administration of the stable oral liquid pharmaceutical composition results in an increase of at least 40% in the percentage of treated human individuals who eliminate pain for at least 24 hours after administration compared to the percentage of human individuals treated with a placebo. In some embodiments, administration of the stable oral liquid pharmaceutical composition results in at least a 10% increase in the percentage of treated human subjects who are pain free for at least 24 hours after administration compared to the percentage of human subjects treated with commercially available migraine treatments (e.g., VIOXX 25 (25 mg), VIOXX 50 (50 mg), and CAMBIA 50 (50 mg)).

[0085] Some embodiments disclosed herein provide methods for treating pain in human subjects, the methods comprising administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one polar solvent, at least one medium chain glyceride, and at least one pharmaceutically acceptable excipient, wherein the stable oral liquid pharmaceutical composition is substantially free of precipitation inhibitors and results in at least 30%, at least 40%, or at least 50% of the human subjects being free of any most bothersome symptom at 2 hours.

[0086] Some embodiments disclosed herein provide methods for treating pain in a human subject, the method comprising administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, at least one solubilizing agent, at least one polar solvent, at least one medium-chain glyceride, and at least one pharmaceutically acceptable excipient, wherein the stable oral liquid pharmaceutical composition is substantially free of a precipitation inhibitor, wherein the therapeutically effective amount of celecoxib is sufficient to relieve the subject of the most bothersome symptoms within 2 hours after administration of the stable oral liquid pharmaceutical composition. In some embodiments, the stable oral liquid pharmaceutical composition comprises a therapeutically effective amount of celecoxib, at least one solubilizing agent in an amount of about 35% w / w to about 45% w / w, at least one polar solvent in an amount of about 25% w / w to about 42% w / w, at least one medium-chain glyceride, and at least one pharmaceutically acceptable excipient, wherein the stable oral liquid pharmaceutical composition is substantially free of a precipitation inhibitor. In some embodiments, the pain is associated with migraine.

[0087] In some embodiments, the therapeutically effective amount of celecoxib is sufficient to eliminate pain in the individual within 2 hours after administration of the stable oral liquid pharmaceutical composition. In some embodiments, the therapeutically effective amount of celecoxib is sufficient to cause partial pain relief in the individual within 2 hours after administration of the stable oral liquid pharmaceutical composition. In some embodiments, administration of the stable oral liquid pharmaceutical composition results in at least 25% of the treated human individuals eliminating the most bothersome symptoms within 2 hours after treatment. In some embodiments, administration of the stable oral liquid pharmaceutical composition results in at least 45% of the treated human individuals eliminating the most bothersome symptoms within 2 hours after treatment. In some embodiments, administration of the stable oral liquid pharmaceutical composition results in an increase of at least 40% in the percentage of treated human individuals whose most bothersome symptoms are eliminated within 2 hours after treatment compared to the percentage of human individuals treated with a placebo. In some embodiments, administration of the stable oral liquid pharmaceutical composition results in at least a 10% increase in the percentage of treated human subjects who are free of the most bothersome symptom within 2 hours after treatment compared to the percentage of human subjects treated with commercially available migraine treatments (e.g., VIOXX 25 (25 mg), VIOXX 50 (50 mg), and CAMBIA 50 (50 mg)). BRIEF DESCRIPTION OF THE DRAWINGS

[0089] Figure 1 The ternary phase diagram is shown. The shaded area is the "stable composition region A" formed by the connecting lines between points (a, b, c, d, e and f).

[0090] Figure 2The ternary phase diagram is shown. The shaded area is the "Stable Composition Region B" formed by the connecting lines between points (a, b, c, d, e and f).

[0091] Figure 3 The ternary phase diagram is shown. The shaded area is the "Stable Composition Region C" formed by the connecting lines between points (a, b, c, d, e, f, g, and h).

[0092] Figure 4 Shown is the pain relief at 2 hours resulting from Example 3 with 120 mg celecoxib (Treatment-1) compared to VIOXX 25, VIOXX 50 and CAMBIA 50, as a percentage of human subjects.

[0093] Figure 5 The percent pain relief at 2 hours resulting from Example 3 with 120 mg celecoxib (Treatment-1) compared to VIOXX 25, VIOXX 50, and CAMBIA 50 is shown as a percentage of human subjects.

[0094] Figure 6 Pain relief at 2 hours and pain relief at 24 hours resulting from Example 3 with 120 mg celecoxib (Treatment-1) compared to VIOXX 25, VIOXX 50 and CAMBIA 50 are shown as a percentage of human subjects.

[0095] Figure 7 Shown is the elimination of the most bothersome symptom (MBS) at 2 hours as a percentage of human subjects resulting from Example 3 with 120 mg celecoxib (Treatment 1). DETAILED DESCRIPTION

[0096] definition

[0097] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

[0098] As used herein, "comprising" is open ended and refers to the elements recited or their structural or functional equivalents, as well as any other element or elements not recited. The terms "having" and "including" should also be considered open ended unless the context indicates otherwise.

[0099] All ranges described herein are inclusive, including those that mention a range "between" two values. As an illustration, a numerical range of 1 to 5 should be interpreted as including not only the explicitly recited values ​​of 1 to 5, but also individual values ​​and subranges within the indicated range. Thus, individual values ​​such as 2, 3, and 4 are included within the numerical range, as well as subranges such as 1-3, 2-4, and 3-5, and individually 1, 2, 3, 4, or 5. This same principle applies to ranges that only recite a single numerical value as a minimum or maximum value.

[0100] As used herein, the terms "a" and "the" are to be understood as including the plural as well as the singular. For example, reference to "an excipient" includes reference to one or more such excipients, and reference to "the carrier" includes reference to one or more such carriers.

[0101] Terms such as "about", "up to", "generally", "substantially" and the like should be interpreted as modifying terms or values ​​so that they are not absolute. These terms are defined by the context and the terms they modify, as understood by those skilled in the art. These terms represent approximations or a degree of deviation, rather than being complete and absolute. These terms include at least the degree of experimental error, technical error, and instrumental error expected for a given experiment, technique, or instrument for measuring a value. The terms may refer to a higher tolerance for variation, depending, for example, on the experimental technique used. Variations on the specific values ​​are understood by those skilled in the art and are within the scope of the invention.

[0102] As used herein, "free" of a particular compound, composition, or excipient means that no individually added portion of the referenced compound, composition, or excipient is present. The term "substantially free" means that less than 1% w / w of a particular compound, composition, or excipient is present, wherein the amount present does not impart any functional value to the composition.

[0103] " Celecoxib " used herein includes base form, and its pharmaceutically acceptable salt, complex, polymorph, hydrate, solvate, enantiomer or racemate.The solid form of the celecoxib used in the composition of the application is not important.For example, celecoxib can be amorphous or crystalline.

[0104] As used herein, the term "pharmaceutically acceptable salts" includes salts which are suitable for contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, etc., within the scope of sound medical judgment, and are well known in the art. The salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting a pharmaceutically active substance having a free base functional group with a suitable organic or inorganic acid.

[0105] As used herein, an "effective amount" or "therapeutically effective amount" of a drug refers to a non-toxic but sufficient amount of the drug to achieve a therapeutic effect in treating a condition for which the drug is known to be effective. In this case, an effective amount is an amount of celecoxib as described below that is sufficient to treat pain in a patient in need thereof, that is, to provide some analgesic measure to at least reduce the patient's perception of pain.

[0106] The term "liquid composition" refers to a liquid composition that is taken with or without further mixing with an aqueous or suitable vehicle prior to oral administration.

[0107] As used herein, the term "stable composition" refers to a composition that does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at pH 2.0 and temperature 37°C ± 0.5°C for at least 60 minutes under stirring at a speed of 50 rpm. The term "stable composition" also refers to a composition that is substantially free of impurities, or contains no more than 5% impurities, or contains impurities at a level acceptable to regulatory agencies such as the United States Food and Drug Administration (US FDA) when stability is evaluated at 40°C and 75% RH (relative humidity) or 25°C and 60% RH (relative humidity).

[0108] As used herein, the term "precipitation inhibitor" refers to a pharmaceutically acceptable excipient that prevents celecoxib from precipitating when orally administered to a human subject or when tested in a simulated gastric fluid at pH 2.0 and 37°C (e.g., fasting state simulated gastric fluid (FaSSGF)) under stirring. Examples of precipitation inhibitors include: polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer Polyoxyethylene-polyoxypropylene block copolymers, Pluronics, polyvinylpyrrolidone, and cellulosic polymers including hydroxypropylcellulose and hydroxypropylmethylcellulose. Possible precipitation inhibitors may also include non-cellulosic polymers that inhibit precipitation.

[0109] As used herein, the term "fasted state simulated gastric fluid (FaSSGF)" refers to a standard in vitro assay used to simulate fasted state gastric fluid to evaluate the stability (or solubility, or suitability) of pharmaceutical formulations for oral delivery. The composition of FaSSGF is 0.1N HCl and 0.05% SLS, and the pH is adjusted with NaOH / HCl.

[0110] As used herein, the term "conventional celecoxib oral composition" or "conventional composition" refers to the celecoxib oral composition sold by GDSearle LLC under the trade name Oral celecoxib capsules sold in the United States, or pharmaceutical equivalents thereof, or therapeutic equivalents thereof, or later approved drugs designated as AB (assessed by the US FDA according to Approved Drug Products with Therapeutic Equivalence Evaluations (34th Edition)), or drugs that have been submitted for marketing approval by the USFDA through an Abbreviated New Drug Application (ANDA) by establishing bioequivalence to such products. In some embodiments, This includes US FDA approved therapeutic or pharmaceutical equivalents thereof. is a registered trademark of GDSearle LLC (a subsidiary of Pfizer Inc. NY), NY 10017, USA. In certain other embodiments, "conventional celecoxib oral composition" or "conventional composition" also includes celecoxib manufactured by Zydus Cadila, Zydus Tower, Ahmedabad, India under the trade name Oral celecoxib capsules for sale. Available strengths are oral capsules containing 50 mg, 100 mg, 200 mg and 400 mg of celecoxib. Available strengths are oral capsules containing 100 mg and 200 mg of celecoxib.

[0111] As used herein, the term "pain" refers to the pain described herein, such as acute pain, migraine, cluster headache, neuropathic pain, postoperative pain, chronic low back pain, herpetic neuralgia, phantom limb pain, central pain, dental pain, neuropathic pain, opioid-resistant pain, visceral pain, surgical pain, bone injury pain, pain during labor and delivery, pain caused by burns (including sunburn), postpartum pain, angina pectoris, genitourinary tract related pain (including cystitis), arthritis pain, inflammatory pain, osteoarthritis pain, juvenile rheumatoid arthritis pain, ankylosing spondylitis pain, primary dysmenorrhea pain, breakthrough pain or any type of cancer pain.

[0112] As used herein, the term "treatment" includes the treatment and / or prevention of physical and / or mental disorders, or the amelioration or elimination of established disorders (once established), or the alleviation of the symptoms characteristic of such disorders.

[0113] As used herein, the term "mammal" shall refer to higher vertebrates of the class mammalia. The term "mammal" includes, but is not limited to, humans.

[0114] As used herein, the term "pain relief" or "pain relief" refers to the patient's report of no pain according to a numeric rating scale for pain ranging from 0 (no pain) to 3 (severe pain), which is based on "Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators", Tfelt-Hansen P, Pascual J, Ramadan N et al., Cephalalgia, 2012; 32(1): 6-38.

[0115] As used herein, the terms "headache relief", "partial pain relief", "partial relief" or "pain relief" are patient reports of pain intensity that is ≥1 level lower than the pre-dose rating on a numeric rating scale for pain ranging from 0 (no pain) to 3 (severe pain), the scale being developed in accordance with "Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators", Tfelt-Hansen P, Pascual J, Ramadan N et al., Cephalalgia, 2012; 32(1): 6-38.

[0116] When the term "maintain" is used in conjunction with a period of time during which pain is eliminated or pain is relieved herein, the period is measured from the beginning of pain elimination or pain relief. For example, if pain elimination is maintained for at least about 2 hours, the period is measured from the time point after administration when the patient does not feel pain. Therefore, if the patient feels pain elimination 2 hours after administration, the period of time during which pain elimination is maintained is measured from the time point 2 hours after administration.

[0117] In addition to the "pain" or "headache" experienced by patients suffering from migraine, patients often suffer from other "most bothersome symptoms" that are unique to the patient and are based on patient reports identifying such most bothersome symptoms, as understood in the art. These symptoms include, but are not necessarily limited to, nausea, vomiting, photophobia (light sensitivity), and phonophobia (sound sensitivity). Other examples of such symptoms include, but are not limited to, sensitivity to odors, sensitivity to touch, blurred vision and other visual phenomena, dizziness, fainting, vertigo, lightheadedness, and mood changes.

[0118] Stable oral liquid pharmaceutical composition

[0119] In some embodiments, the present application provides a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib. In some embodiments, the stable oral liquid pharmaceutical composition disclosed herein comprises at least one solubilizer, at least one medium chain glyceride, at least one polar solvent and / or at least one pharmaceutically acceptable excipient.

[0120] Without being limited by a particular theory, it is expected that the stable oral liquid pharmaceutical compositions disclosed herein show improved dissolution characteristics, such as when orally administered to human subjects. In some embodiments, the stable oral liquid pharmaceutical compositions disclosed herein do not show any precipitation for a prolonged period of time in simulated gastric fluid (SGF). For example, the stable oral liquid pharmaceutical compositions disclosed herein do not show any precipitation for a prolonged period of time in simulated gastric fluid (SGF) for at least 10 min, at least 20 min, at least 30 min, at least 40 min, at least 50 min, at least 60 min, at least 90 min, at least 2 hr, at least 3 hr, at least 4 hr, at least 5 hr, at least 6 hr, at least 12 hr, at least 24 hr or longer. In some embodiments, the stable oral liquid pharmaceutical compositions disclosed herein do not show any precipitation for a prolonged period of time in simulated gastric fluid (FaSSGF) in the fasted state. For example, the stable oral liquid pharmaceutical compositions disclosed herein do not show any precipitation in fasting state simulated gastric fluid (FaSSGF) for at least 10 min, at least 20 min, at least 30 min, at least 40 min, at least 50 min, at least 60 min, at least 90 min, at least 2 hr, at least 3 hr, at least 4 hr, at least 5 hr, at least 6 hr, at least 12 hr, at least 24 hr, or longer.

[0121] In some embodiments, the stable oral liquid pharmaceutical composition disclosed herein does not show any precipitation in a low pH environment. For example, the stable oral liquid pharmaceutical composition disclosed herein lasts for at least 10min, at least 20min, at least 30min, at least 40min, at least 50min, at least 60min, at least 90min, at least 2hr, at least 3hr, at least 4hr, at least 5hr, at least 6hr, at least 12hr, at least 24hr or longer in a fasting state simulated gastric juice (FaSSGF) with a pH of 1.0-6.0. It does not show any precipitation. In some embodiments, the stable oral liquid pharmaceutical composition disclosed herein lasts for at least 10min, at least 20min, at least 30min, at least 40min, at least 50min, at least 60min, at least 90min, at least 2hr, at least 3hr, at least 4hr, at least 5hr, at least 6hr, at least 12hr, at least 24hr or longer in a fasting state simulated gastric juice (FaSSGF) with a pH of 1.0-5.0. It does not show any precipitation. In some embodiments, the stable oral liquid pharmaceutical compositions disclosed herein do not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 1.0-4.0 for at least 10 min, at least 20 min, at least 30 min, at least 40 min, at least 50 min, at least 60 min, at least 90 min, at least 2 hr, at least 3 hr, at least 4 hr, at least 5 hr, at least 6 hr, at least 12 hr, at least 24 hr or longer. In some embodiments, the stable oral liquid pharmaceutical compositions disclosed herein do not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 1.0-3.0 for at least 10 min, at least 20 min, at least 30 min, at least 40 min, at least 50 min, at least 60 min, at least 90 min, at least 2 hr, at least 3 hr, at least 4 hr, at least 5 hr, at least 6 hr, at least 12 hr, at least 24 hr or longer. In some embodiments, the stable oral liquid pharmaceutical compositions disclosed herein do not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0-3.0 for at least 10 min, at least 20 min, at least 30 min, at least 40 min, at least 50 min, at least 60 min, at least 90 min, at least 2 hr, at least 3 hr, at least 4 hr, at least 5 hr, at least 6 hr, at least 12 hr, at least 24 hr, or longer.In some embodiments, the stable oral liquid pharmaceutical compositions disclosed herein do not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at pH 2.0 for at least 10 min, at least 20 min, at least 30 min, at least 40 min, at least 50 min, at least 60 min, at least 90 min, at least 2 hr, at least 3 hr, at least 4 hr, at least 5 hr, at least 6 hr, at least 12 hr, at least 24 hr, or longer.

[0122] Without being limited by a particular theory, the stable oral liquid pharmaceutical compositions disclosed herein are substantially free of precipitation inhibitors. In some embodiments, the stable oral liquid pharmaceutical compositions disclosed herein are completely free of precipitation inhibitors. In some embodiments, the celecoxib compositions of the present application are substantially free of precipitation inhibitors such as polyoxyethylene-polyoxypropylene block copolymers, pluronics, polyvinyl pyrrolidone, hydroxypropyl cellulose and hydroxypropyl methylcellulose. In some embodiments, the celecoxib compositions of the present application are substantially free of precipitation inhibitors, including polyethylene caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers. Polyoxyethylene-polyoxypropylene block copolymers, Pluronics, polyvinylpyrrolidone, cellulosic polymers (including hydroxypropyl cellulose and hydroxypropyl methylcellulose) and non-cellulosic polymers.

[0123] In some embodiments, the present application provides a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib, wherein the average oil droplet size of the composition is no greater than 500 nm when tested in 250 ml of fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C under stirring at a speed of 50 rpm.

[0124] In some embodiments, the present application provides a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib, wherein the composition does not show any precipitation in a dissolution medium or fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C under stirring at a speed of 50 rpm, when measured at a time point of 30 min, 60 min, 90 min, 120 min, 180 min or 240 min; and the composition is substantially free of precipitation inhibitors such as polyoxyethylene-polyoxypropylene block copolymers, pluronics, polyvinyl pyrrolidone, hydroxypropyl cellulose and hydroxypropyl methylcellulose.

[0125] In some embodiments, the present application provides a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, wherein the composition does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C when measured at a time point of 30 min, 60 min, 90 min, 120 min, 180 min or 240 min under stirring at a speed of 50 rpm; and the composition is substantially free of precipitation inhibitors such as polyoxyethylene-polyoxypropylene block copolymers, pluronics, polyvinyl pyrrolidone, hydroxypropyl cellulose and hydroxypropyl methylcellulose.

[0126] In some embodiments, the present application provides a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C when measured at a time point of 30 min, 60 min, 90 min, 120 min, 180 min or 240 min under stirring at a speed of 50 rpm; and the composition is substantially free of precipitation inhibitors such as polyoxyethylene-polyoxypropylene block copolymers, pluronics, polyvinyl pyrrolidone, hydroxypropyl cellulose and hydroxypropyl methylcellulose.

[0127] In some embodiments, the present application provides a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C when measured at a time point of 30 min, 60 min, 90 min, 120 min, 180 min or 240 min under stirring at a speed of 50 rpm; and the composition is substantially free of precipitation inhibitors such as polyoxyethylene-polyoxypropylene block copolymers, pluronics, polyvinyl pyrrolidone, hydroxypropyl cellulose and hydroxypropyl methylcellulose.

[0128] The oral celecoxib pharmaceutical composition of the present application can be formulated in the form of a solution, a suspension, an emulsion or a liquid mixture.

[0129] Medium Chain Glycerides

[0130] In some embodiments, the stable oral liquid pharmaceutical composition of the present application also includes at least one medium-chain glyceride. As used herein, medium-chain glycerides can refer to medium-chain monoglycerides, medium-chain diglycerides and / or medium-chain triglycerides (MCT). MCT is such a triglyceride, and its fatty acid has an aliphatic tail of 6-12 carbon atoms. MCT comprises a glycerol backbone and three fatty acids. In the case of MCT, 2 or 3 fatty acid chains connected to glycerol are medium chains in length. Exemplary medium-chain fatty acids include caproic acid, caprylic acid, capric acid, lauric acid, etc. It should be understood that medium-chain glycerides (e.g., MCT) can improve the solubility of the stable oral liquid pharmaceutical composition disclosed herein when orally administered to human individuals or in simulated gastric fluid (e.g., fasted state simulated gastric fluid (FaSSGF)).

[0131] The medium chain glycerides can be present in various concentrations in the stable oral liquid pharmaceutical compositions disclosed herein. For example, the stable oral liquid pharmaceutical compositions disclosed herein can include at least 10 weight %, at least 20 weight %, at least 30 weight %, at least 40 weight %, at least 50 weight %, at least 60 weight %, at least 70 weight %, at least 80 weight %, at least 90 weight % or a percentage between any two of the above values ​​of medium chain glycerides based on the total weight of the composition.

[0132] In some embodiments, the celecoxib composition of the present application comprises at least one medium-chain glyceride in an amount of about 5 wt % to about 75 wt %, about 5 wt % to about 65 wt %, about 5 wt % to about 55 wt %, about 5 wt % to about 45 wt % or about 5 wt % to about 35 wt % of the total weight of the composition.

[0133] In some embodiments, the celecoxib composition of the present application further comprises medium chain glycerides having at least one medium chain monoglyceride, medium chain diglyceride, medium chain triglyceride or a mixture thereof.

[0134] Suitable examples of medium chain monoglycerides, medium chain diglycerides or medium chain triglycerides (MCT) used in the compositions of the present application are known in the art. Non-limiting examples of medium chain monoglycerides, medium chain diglycerides or medium chain triglycerides (MCT) include, but are not limited to, even-numbered fatty acids and odd-numbered fatty acids, such as fatty acids containing C4 (butyric acid), C5 (pentanoic acid), C6 (caproic acid), C7 (heptanoic acid), C8 (octanoic acid), C9 (nonanoic acid), C10 (decanoic acid), C11 (undecanoic acid) or C12 (lauric acid, dodecanoic acid); and even-numbered fatty acids and odd-numbered fatty acids (containing 2 to 12 carbon atoms) esters formed with glycerol, such as monocaprylic acid glyceride, dicaprylic acid glyceride, propylene glycol heptanoate, monocapric acid glyceride, caprylic acid / capric acid glyceride, which can be used as CAPMUL The obtained medium chain monoglycerides and medium chain diglycerides, propylene glycol monocaprylate and propylene glycol dicaprylate, tricaprylin, tricaprylic acid / capric acid glyceride, tricaprylic acid / tricapric acid glyceride, tricaprylic acid / tricapric acid glyceride, PEG-8 caprylic acid / capric acid glyceride. In addition, the medium chain glyceride component can be a naturally occurring composition containing monoglycerides or diglycerides or triglycerides, which is obtained, for example, from milk fat, soybean oil, coconut oil, etc.

[0135] In some embodiments, the celecoxib composition of the present application comprises at least one medium chain glyceride selected from lauroyl macrogol glyceride, monocaprylin, tricaprylic / tricaprin, or a combination thereof.

[0136] Alternatively, the glyceride component comprises at least one industrially prepared glyceride, or a mixture of naturally obtained glycerides and industrially prepared glycerides. The glycerides may be prepared by the inter-esterification of C4 to C12 chain fatty acids such as capryloyl caproyl polyethylene glycol-8-glyceride.

[0137] Polar solvents

[0138] In some embodiments, the stable oral liquid pharmaceutical composition of the application also comprises at least one polar solvent.Not subject to the constraint of any particular theory, in the celecoxib composition according to the application, adding a polar solvent additionally helps to delay the beginning of the settling time.In some embodiments, compared with the celecoxib composition that is substantially free of polar solvents, the beginning of precipitation is delayed at least about 1-10 hours.In some embodiments, the beginning of the settling time can be delayed by the polar solvent by at least about 1 hour, at least about 2 hours, at least about 3 hours, at least about 4 hours, at least about 5 hours, at least about 6 hours or longer.

[0139] Suitable examples of polar solvents that can be used in the present application are selected from propylene glycol, polyethylene glycol with a molecular weight of 400 to 1000, glycerol, C2 to C8 monohydric alcohols and polyhydric alcohols (e.g., ethanol), C7 to C8 in a linear or branched configuration. 18 Alcohol, water, and any combination thereof.

[0140] The polar solvent can be present in the stable oral liquid pharmaceutical composition disclosed herein at various concentrations. For example, the stable oral liquid pharmaceutical composition disclosed herein can include at least 10 weight %, at least 20 weight %, at least 30 weight %, at least 40 weight %, at least 50 weight %, at least 60 weight %, at least 70 weight %, at least 80 weight %, at least 90 weight %, or a percentage between any two of the above values ​​of polar solvent, based on the total weight of the composition.

[0141] In some embodiments, the celecoxib composition of the present application comprises a polar solvent in an amount of about 20 wt % to about 80 wt %, about 20 wt % to about 70 wt %, about 20 wt % to about 60 wt %, about 20 wt % to about 50 wt %, or about 20 wt % to about 40 wt %, based on the total weight of the composition.

[0142] Solubilizer

[0143] In some embodiments, the stable oral liquid pharmaceutical composition of the present application comprises at least one solubilizer selected from the group consisting of a nonionic surfactant, an anionic surfactant, a cationic surfactant, and a zwitterionic surfactant, or a mixture thereof.

[0144] Suitable non-limiting examples of solubilizers for use in the compositions of the present application include, but are not limited to, polyethoxylated fatty acids, such as esters of lauric acid, oleic acid, and stearic acid; PEG-fatty acid diesters, such as PEG-20 dilaurate, PEG-fatty acid monoesters and diester mixtures; alcohol-oil transesterification products, such as PEG-35 castor oil, polyoxyethylene 35 castor oil, polyoxyethylene 40 hydrogenated castor oil, etc.; polyglycerolated fatty acids, such as polyglycerol oleate, etc.; propylene glycol fatty acid esters, such as propylene glycol monolaurate, etc.; propylene glycol ester-glycerol; Oil ester mixtures, such as oleic acid esters of propylene glycol and glycerol, etc.; sterols and sterol derivatives, such as PEG-24 cholesterol ester, etc.; polyethylene glycol sorbitan fatty acid esters, such as PEG-20 sorbitan monolaurate, etc.; polyethylene glycol alkyl ethers, such as PEG-3 oleyl ether, etc.; sugar esters, such as sucrose monopalmitate, etc.; polyethylene glycol alkylphenols, such as octoxynol-1, etc.; sorbitan fatty acid esters, such as sorbitan monolaurate; lower alcohol fatty acid esters, such as ethyl oleate, etc.; anionic surfactants, including fatty acid salts and bile salts. Other exemplary solubilizers include, but are not limited to: polyoxyethylene alkyl ethers; polyethylene glycol fatty acid esters; polyethylene glycol glycerol fatty acid esters; polyoxyethylene sorbitan fatty acid esters; polyglycerol fatty acid esters; polyoxyethylene glycerides; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; alkyl glycosides; alkyl maltosides; alkyl thioglucosides; lauric acid polyethylene glycol glyceride. Ionic surfactants include sodium oleate, sodium lauryl sulfate, sodium lauryl sarcosinate, sodium dioctyl sulfosuccinate, sodium cholate, and sodium taurocholate; 44 / 14, etc.

[0145] In some embodiments, the celecoxib composition of the present application comprises at least one solubilizer selected from: glycerol polyethylene glycol ricinoleate, polyethylene glycol glycerol ricinoleate Ph.Eur., polyoxyl 35 castor oil, lauroyl polyoxyl-32 glyceride, lauroyl macrogol-32 glyceride, polyoxyl 40 hydrogenated castor oil, polyoxyl 35 castor oil, PEG-40 hydrogenated castor oil, or a mixture thereof.

[0146] The at least one solubilizing agent can be present in various concentrations in the stable oral liquid pharmaceutical composition disclosed herein. For example, the stable oral liquid pharmaceutical composition disclosed herein may include at least 10 weight %, at least 20 weight %, at least 30 weight %, at least 40 weight %, at least 50 weight %, at least 60 weight %, at least 70 weight %, at least 80 weight %, at least 90 weight %, or at least one solubilizing agent of the percentage between any two of the above values, accounting for the total weight of the composition. In some embodiments, the celecoxib composition of the present application includes an amount of about 10 weight % to about 70 weight %, about 20 weight % to about 60 weight %, about 20 weight % to about 50 weight %, about 30 weight % to about 40 weight % of the total weight of the composition.

[0147] In certain aspects of the above embodiments, the celecoxib composition of the present application comprises a solubilizer and a polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00.

[0148] In another aspect of the above embodiment, the present application provides a stable oral liquid pharmaceutical composition of celecoxib, comprising a therapeutically effective amount of celecoxib, at least one solubilizer and at least one polar solvent, wherein the composition comprises the solubilizer and the polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00.

[0149] In certain aspects of the above embodiments, the present application provides a stable oral liquid pharmaceutical composition of celecoxib, comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one polar solvent and at least one pharmaceutically acceptable excipient, wherein the composition comprises the solubilizer and the polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00.

[0150] In one aspect of the above embodiment, the composition of the present application comprises celecoxib in an amount of about 1 wt % to about 80 wt %, about 2 wt % to about 70 wt %, about 2 wt % to about 50 wt %, about 2 wt % to about 40 wt %, or about 2 wt % to about 8 wt % of the total weight of the composition.

[0151] In some embodiments, the present application provides a stable oral liquid pharmaceutical composition of celecoxib, comprising a therapeutically effective amount of celecoxib, at least one solubilizer, and at least one pharmaceutically acceptable excipient, wherein the composition comprises the solubilizer and celecoxib in a weight ratio of about 4.0:1.0 to about 20:1.0.

[0152] In some embodiments, the celecoxib composition of the present application comprises at least one medium chain glyceride and celecoxib in a weight ratio of about 2.0: 1.0 to about 20: 1.0. In some embodiments, the composition of the present application comprises at least one medium chain glyceride and celecoxib in a weight ratio of about 2.0: 1.0 to about 10.0: 1.0.

[0153] In some embodiments, the celecoxib composition of the present application comprises at least one solubilizing agent and at least one medium chain glyceride in a weight ratio of about 0.05:1.0 to about 20:1.0. In some embodiments, the celecoxib composition of the present application comprises at least one solubilizing agent and at least one medium chain glyceride in a weight ratio of about 0.05:1.0 to about 10.0:1.0.

[0154] In some embodiments, the celecoxib composition of the present application comprises at least one solubilizing agent and celecoxib in a weight ratio of about 4.0:1.0 to about 20:1.0.

[0155] In some embodiments, the present application provides a pharmaceutical composition of celecoxib, comprising:

[0156] a. a therapeutically effective amount of celecoxib;

[0157] b. at least one solubilizing agent in an amount of about 35% w / w to about 45% w / w;

[0158] c. at least one polar solvent in an amount of about 25% w / w to about 42% w / w; and

[0159] d. at least one pharmaceutically acceptable excipient,

[0160] The solubilizer and the polar solvent are present in a weight ratio of about 0.60:1.00 to about 1.8:1.00, and do not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C±0.5°C for at least 60 minutes under stirring at a speed of 50 rpm.

[0161] Improved pharmacokinetic parameters

[0162] The stable oral liquid pharmaceutical compositions disclosed herein may have various pharmacokinetic parameters. In some embodiments, the stable oral liquid pharmaceutical compositions disclosed herein have improved pharmacokinetic parameters compared to conventional celecoxib oral compositions, for example, AUC (0-15min) , AUC (0-30min) , AUC (0-1hr) , AUC (0-2hr) , AUC (0-t) , AUC (0-∞) 、T lag 、T max wait.

[0163] In some embodiments, the stable oral liquid pharmaceutical compositions disclosed herein provide T as described below when orally administered to a human subject under fasting conditions: lag : no more than 60 minutes, no more than 30 minutes, no more than 20 minutes, no more than 10 minutes, no more than 8 minutes, no more than 6 minutes, no more than 5 minutes, no more than 4 minutes, no more than 3 minutes, no more than 2 minutes, no more than 1 minute or less. In some embodiments, the stable oral liquid pharmaceutical composition disclosed herein, when orally administered to a human subject under fasting conditions, provides the following T max : less than about 120 minutes, less than about 90 minutes, less than about 80 minutes, less than about 70 minutes, less than about 60 minutes, less than about 50 minutes, less than about 40 minutes, less than about 30 minutes, less than about 20 minutes or less. In some embodiments, the stable oral liquid pharmaceutical composition disclosed herein, when orally administered to a human subject under fasting conditions, provides an AUC as described below: (0-15min) : at least about 1 ng.h / ml, at least about 2 ng.h / ml, at least about 5 ng.h / ml, at least about 10 ng.h / ml, at least 20 ng.h / ml, at least about 30 ng.h / ml, at least about 40 ng.h / ml, at least about 50 ng.h / ml, at least about 100 ng.h / ml, at least about 200 ng.h / ml or more, or a range between any two of the above values. In some embodiments, the stable oral liquid pharmaceutical compositions disclosed herein provide an AUC as described below when orally administered to a human subject under fasting conditions: (0-30min): at least about 10 ng.h / ml, at least about 20 ng.h / ml, at least about 30 ng.h / ml, at least about 40 ng.h / ml, at least about 50 ng.h / ml, at least about 60 ng.h / ml, at least about 70 ng.h / ml, at least about 80 ng.h / ml, at least about 90 ng.h / ml, at least about 100 ng.h / ml, at least about 200 ng.h / ml, at least about 500 ng.h / ml or more, or a range between any two of the above values. In some embodiments, the stable oral liquid pharmaceutical compositions disclosed herein provide an AUC as described below when orally administered to a human subject under fasting conditions: (0-1hr) : at least about 100 ng.h / ml, at least about 200 ng.h / ml, at least about 300 ng.h / ml, at least about 400 ng.h / ml, at least about 500 ng.h / ml, at least about 600 ng.h / ml, at least about 700 ng.h / ml, at least about 800 ng.h / ml, at least about 900 ng.h / ml, at least about 1000 ng.h / ml, at least about 1500 ng.h / ml, at least about 2000 ng.h / ml, at least about 3000 ng.h / ml, at least about 4000 ng.h / ml or more, or a range between any two of the above values. In some embodiments, the stable oral liquid pharmaceutical compositions disclosed herein provide an AUC as described below when orally administered to a human subject under fasting conditions. (0-2hr) : at least about 500 ng.h / ml, at least about 600 ng.h / ml, at least about 700 ng.h / ml, at least about 800 ng.h / ml, at least about 900 ng.h / ml, at least about 1000 ng.h / ml, at least about 1500 ng.h / ml, at least about 2000 ng.h / ml, at least about 3000 ng.h / ml, at least about 4000 ng.h / ml, at least about 5000 ng.h / ml, at least about 6000 ng.h / ml, at least about 7000 ng.h / ml, at least about 8000 ng.h / ml or more, or a range between any two of the above values. In some embodiments, the stable oral liquid pharmaceutical compositions disclosed herein provide an AUC as described below when orally administered to a human subject under fasting conditions. (0-t): at least about 500 ng.h / ml, at least about 600 ng.h / ml, at least about 700 ng.h / ml, at least about 800 ng.h / ml, at least about 900 ng.h / ml, at least about 1000 ng.h / ml, at least about 1500 ng.h / ml, at least about 2000 ng.h / ml, at least about 3000 ng.h / ml, at least about 4000 ng.h / ml, at least about 5000 ng.h / ml, at least about 6000 ng.h / ml, at least about 7000 ng.h / ml, at least about 8000 ng.h / ml or more, or a range between any two of the above values. In some embodiments, the stable oral liquid pharmaceutical compositions disclosed herein provide an AUC as described below when orally administered to a human subject under fasting conditions. (0-∞) : at least about 500 ng.h / ml, at least about 600 ng.h / ml, at least about 700 ng.h / ml, at least about 800 ng.h / ml, at least about 900 ng.h / ml, at least about 1000 ng.h / ml, at least about 1500 ng.h / ml, at least about 2000 ng.h / ml, at least about 3000 ng.h / ml, at least about 4000 ng.h / ml, at least about 5000 ng.h / ml, at least about 6000 ng.h / ml, at least about 7000 ng.h / ml, at least about 8000 ng.h / ml or more, or a range between any two of the above values.

[0164] In some embodiments, the stable oral liquid pharmaceutical compositions disclosed herein have a release rate of not less than 50%, not less than 60%, not less than 70%, not less than 80%, not less than 90% over a period of 10 minutes when orally administered to a human subject under fasting conditions. In some embodiments, the stable oral liquid pharmaceutical compositions disclosed herein have a release rate of not less than 50%, not less than 60%, not less than 70%, not less than 80%, not less than 90% over a period of 15 minutes when orally administered to a human subject under fasting conditions. In some embodiments, the stable oral liquid pharmaceutical compositions disclosed herein have a release rate of not less than 50%, not less than 60%, not less than 70%, not less than 80%, not less than 90% over a period of 10 minutes in 900 ml of 0.01 N HCl with 0.5% sodium lauryl sulfate when tested in a USP Type 2 apparatus with a sinker at 50 rpm and 37°C. In some embodiments, the stable oral liquid pharmaceutical composition disclosed herein has a release rate of not less than 50%, not less than 60%, not less than 70%, not less than 80%, not less than 90% in 900 ml of 0.01N HCl with 0.5% sodium lauryl sulfate over a period of 15 minutes when tested in a USP Type 2 apparatus with a sinker at 50 rpm and 37°C.

[0165] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein, compared with conventional celecoxib compositions (such as Compared with oral capsules, the composition provides similar or higher AUC (0-15min) , AUC (0-30min) , AUC (0-1小时) and AUC (0-2小时) .

[0166] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the AUC of the composition is (0-15min) is a conventional celecoxib composition (such as Oral capsules) is at least 50 times higher.

[0167] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the AUC of the composition is (0-30min) is a conventional celecoxib composition (such as oral capsules) is at least 12 times higher.

[0168] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the AUC of the composition is(0-1hr) is a conventional celecoxib composition (such as oral capsules) is at least 5 times higher.

[0169] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the AUC of the composition is (0-2hr) is a conventional celecoxib composition (such as Oral capsules) is at least 1.5 times higher.

[0170] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the AUC of the composition is (0-15min) , AUC (0-30min) , AUC (0-1小时) and AUC (0-2小时) Compared with a conventional celecoxib composition containing 400 mg celecoxib (such as 400 mg oral capsule) is similar or higher.

[0171] In some embodiments, the present application provides an oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition provides at least one of the following pharmacokinetic parameters when orally administered to a human subject under fasting conditions:

[0172] a) AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0173] b) AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0174] c) AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0175] d) AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0176] e) an AUC of at least about 2000 ng.h / mL (0-t) ;

[0177] f) an AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0178] g) T not exceeding 8 minutes lag .

[0179] In some embodiments, the present application provides an oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition comprises the solubilizer and the polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00, and provides at least one of the following pharmacokinetic parameters when orally administered to a human subject under fasting conditions:

[0180] a) AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0181] b) AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0182] c) AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0183] d) AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0184] e) an AUC of at least about 2000 ng.h / mL (0-t) ;

[0185] f) an AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0186] g) T not exceeding 8 minutes lag .

[0187] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, and at least one pharmaceutically acceptable excipient; wherein, when tested in a USP type 2 apparatus with a sinker at 50 rpm and 37° C., the composition is 900 ml of 0.01 N HCl with 0.5% sodium lauryl sulfate.

[0188] a) release not less than 70% over a 10 minute period; or

[0189] b) not less than 80% is released over a period of 15 minutes.

[0190] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient; wherein when tested in a USP type 2 apparatus with a sinker at 50 rpm and 37° C., the composition is in 900 ml of 0.01 N HCl with 0.5% sodium lauryl sulfate.

[0191] a) release not less than 70% over a 10 minute period; or

[0192] b) not less than 80% is released over a period of 15 minutes.

[0193] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition provides an AUC of at least about 10 ng.h / ml when orally administered to a human subject under fasting conditions. (0-15min) .

[0194] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition provides an AUC of about 10 ng.h / ml to about 80 ng.h / ml when orally administered to a human subject under fasting conditions. (0-15min) .

[0195] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition provides an AUC of at least about 80 ng.h / ml when orally administered to a human subject under fasting conditions. (0-30min) .

[0196] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition provides an AUC of about 80 ng.h / ml to about 400 ng.h / ml when orally administered to a human subject under fasting conditions. (0-30min) .

[0197] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition provides an AUC of at least about 400 ng.h / ml when orally administered to a human subject under fasting conditions. (0-1hr) .

[0198] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition provides an AUC of about 400 ng.h / ml to about 1500 ng.h / ml when orally administered to a human subject under fasting conditions. (0-1hr) .

[0199] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition provides an AUC of at least about 1000 ng.h / ml when orally administered to a human subject under fasting conditions. (0-2hr) .

[0200] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition provides an AUC of about 1000 ng.h / ml to about 4000 ng.h / ml when orally administered to a human subject under fasting conditions. (0-2hr) .

[0201] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition provides an AUC of at least about 2000 ng.h / ml when orally administered to a human subject under fasting conditions. (0-t) .

[0202] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition has an AUC of at least about 2000 ng.h / ml when orally administered to a human subject under fasting conditions. (0-∞) .

[0203] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition provides a T of no more than 10 minutes when orally administered to a human subject under fasting conditions. lag .

[0204] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition provides a T of no more than 8 minutes when orally administered to a human subject under fasting conditions. lag .

[0205] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizing agent, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition provides a T of no more than 5 minutes when orally administered to a human subject under fasting conditions. lag .

[0206] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizing agent, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition provides a T of less than about 90 minutes when orally administered to a human subject under fasting conditions. max .

[0207] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition provides a T of less than about 60 minutes when orally administered to a human subject under fasting conditions. max .

[0208] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition comprises a solubilizer and a polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00; and the composition provides an AUC of at least about 10 ng.h / ml when orally administered to a human subject under fasting conditions. (0-15min) .

[0209] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition comprises a solubilizer and a polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00; and the composition provides an AUC of about 10 ng.h / ml to about 80 ng.h / ml when orally administered to a human subject under fasting conditions. (0-15min) .

[0210] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition comprises a solubilizer and a polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00; and the composition provides an AUC of at least 80 ng.h / ml when orally administered to a human subject under fasting conditions. (0-30min) .

[0211] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition comprises a solubilizer and a polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00; and the composition provides an AUC of about 80 ng.h / ml to about 400 ng.h / ml when orally administered to a human subject under fasting conditions. (0-30min) .

[0212] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition comprises a solubilizer and a polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00; and the composition provides an AUC of at least about 400 ng.h / ml when orally administered to a human subject under fasting conditions. (0-1hr) .

[0213] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition comprises a solubilizer and a polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00; and the composition provides an AUC of about 400 ng.h / ml to about 1500 ng.h / ml when orally administered to a human subject under fasting conditions.(0-1hr) .

[0214] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition comprises a solubilizer and a polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00; and the composition provides an AUC of at least about 1000 ng.h / ml when orally administered to a human subject under fasting conditions. (0-2hr) .

[0215] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition comprises a solubilizer and a polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00; and the composition provides an AUC of about 1000 ng.h / ml to about 4000 ng.h / ml when orally administered to a human subject under fasting conditions. (0-2hr) .

[0216] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition comprises a solubilizer and a polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00; and provides an AUC of at least about 2000 ng.h / ml when orally administered to a human subject under fasting conditions. (0-t) .

[0217] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition comprises a solubilizer and a polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00; and the composition provides an AUC of at least about 2000 ng.h / ml when orally administered to a human subject under fasting conditions. (0-∞) .

[0218] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition comprises a solubilizer and a polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00; and the composition provides a T of no more than 10 minutes when orally administered to a human subject under fasting conditions. lag .

[0219] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition comprises a solubilizer and a polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00; and the composition provides a T of no more than 8 minutes when orally administered to a human subject under fasting conditions. lag .

[0220] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition comprises a solubilizer and a polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00; and the composition provides a T of no more than 5 minutes when orally administered to a human subject under fasting conditions. lag .

[0221] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition comprises a solubilizer and a polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00; and the composition provides a T of less than 90 minutes when orally administered to a human subject under fasting conditions. max .

[0222] Improved physical properties

[0223] In some embodiments, the stable oral liquid pharmaceutical compositions disclosed herein have improved physical properties, such as droplet size, viscosity, etc. D50 and D90 represent the median or 50th and 90th percentiles, respectively, of the oil droplet size distribution measured by volume. This means that the term "D50" is defined as the size in nm (nanometers) below which 50% of the oil droplets exist by volume, and similarly, the term "D90" is defined as the size in nm (nanometers) below which 90% of the oil droplets exist by volume. For example, the oil droplet size can be measured using a particle size analyzer, such as the proprietary Zetasizer available from Malvern Instruments Ltd. TM Device, measured by laser scattering.

[0224] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, and at least one pharmaceutically acceptable excipient, wherein the composition does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C for at least 60 minutes under stirring at a speed of 50 rpm, and the average oil droplet size of the composition does not exceed 500 nm.

[0225] The ternary phase diagram was drawn ( Figure 1 ), which describes a "stable composition region A". The "stable composition region A" is defined by the shaded area or by the area between the connecting lines between the six points (a, b, c, d, e and f). Any composition outside this region does not form an acceptable composition because the onset of the settling time is less than 60 minutes; or the D50 oil droplet size is greater than about 250nm or the D90 oil droplet size is greater than about 500nm.

[0226] In one embodiment, the stable composition of celecoxib according to the present application comprises

[0227] a) a therapeutically effective amount of celecoxib, at least one solubilizing agent, and at least one medium chain glyceride; and

[0228] b) a polar solvent comprising a mixture of ethanol and glycerol;

[0229] wherein the composition falls within Figure 1In the shaded area of ​​the phase diagram shown, wherein the boundary of the stable composition is defined by the shaded area or by the area between the connecting lines between the six points (a, b, c, d, e and f), wherein the composition comprises about 1% w / w to about 80% w / w celecoxib and corresponds to the following base composition: weight percentages of ethanol:glycerol: for a, 0.200:0.024:0.712, for b, 0.200:0.376:0.360, for c, 0.200:0.400:0.336, for d, 0.536:0.400:0.000, for e, 0.900:0.036:0.00, and for f, 0.900:0.00:0.036.

[0230] Draw a ternary phase diagram Figure 2 , which describes a "stable composition region B". The "stable composition region B" is defined by the shaded area or by the area between the connecting lines between the six points (a, b, c, d, e and f). Any composition outside this region does not form an acceptable composition because the onset of the settling time is less than 60 minutes; or the D50 oil droplet size is greater than about 125nm or the D90 oil droplet size is greater than about 250nm.

[0231] In one embodiment, the stable composition of celecoxib according to the present application comprises

[0232] a) a therapeutically effective amount of celecoxib, at least one solubilizing agent, and at least one medium chain glyceride; and

[0233] b) a polar solvent comprising a mixture of ethanol and glycerol;

[0234] wherein the composition falls within Figure 2 In the shaded area of ​​the phase diagram shown, wherein the boundary of the stable composition is defined by the shaded area or by the area between the connecting lines between the six points (a, b, c, d, e and f), wherein the composition comprises about 1% w / w to about 80% w / w of celecoxib and corresponds to the following base composition: weight percentages of ethanol:glycerol: for a, 0.226:0.000:0.710, for b, 0.235:0.371:0.330, for c, 0.236:0.400:0.300, for d, 0.536:0.400:0.000, for e, 0.865:0.071:0.000, and for f, 0.836:0.000:0.100.

[0235] The ternary phase diagram was drawn ( Figure 3), which describes a "stable composition region C". The "stable composition region C" is defined by the shaded area or by the area between the connecting lines between the eight points (a, b, c, d, e, f, g, and h). Any composition outside this region does not form an acceptable composition because the onset of the settling time is less than 60 minutes; or the D50 oil droplet size is greater than about 50nm or the D90 oil droplet size is greater than about 100nm.

[0236] In one embodiment, the stable composition of celecoxib according to the present application comprises

[0237] a) a therapeutically effective amount of celecoxib, at least one solubilizing agent, and at least one medium chain glyceride; and

[0238] b) a polar solvent comprising a mixture of ethanol and glycerol;

[0239] wherein the composition falls within Figure 3 In the phase diagram shown, the boundaries of the stable composition are defined by the shaded area or by the area between the connecting lines between the eight points (a, b, c, d, e, f, g and h), wherein the composition comprises about 1% w / w to about 80% w / w celecoxib and corresponds to the following base composition: weight percentages of ethanol:glycerol: for a, 0.300:0.000:0.636, for b, 0.385:0.206:0.345, for c, 0.283:0.399:0.254, for d, 0.536:0.400:0.000, for e, 0.745:0.191:0.000, for f, 0.778:0.144:0.014, for g, 0.817:0.056:0.063, and for h, 0.636:0.000:0.300.

[0240] In some embodiments, the stable composition is described by "stable composition region A", "stable composition region B", "stable composition region C" in the region of the phase diagram, wherein the composition comprises a reduced dose of celecoxib, wherein the AUC of the reduced dose of celecoxib is (0-15min) , AUC (0-30min) , AUC (0-1hour) and AUC (0-2hour) Compared with conventional celecoxib compositions (such as Oral capsules) are similar or higher.

[0241] In another aspect of the above embodiment, the stable composition is described by "Stable Composition Region A", "Stable Composition Region B", "Stable Composition Region C" shown in the shaded area of ​​the phase diagram, wherein the composition is substantially free of precipitation inhibitors, such as polyoxyethylene-polyoxypropylene block copolymers, Pluronics, polyvinyl pyrrolidone, hydroxypropyl cellulose and hydroxypropyl methylcellulose.

[0242] In another aspect of the above embodiment, the stable composition is described by the "Stable Composition Region A", "Stable Composition Region B", "Stable Composition Region C" shown in the shaded areas of the phase diagram, wherein when tested in a USP Type 2 apparatus with a sinker at 50 rpm and 37° C., the composition is stable in 900 ml of 0.01 N HCl with 0.5% sodium lauryl sulfate.

[0243] a) release not less than 70% over a 10 minute period; or

[0244] b) not less than 80% is released over a period of 15 minutes.

[0245] In another aspect of the above embodiment, the stable composition is described by "stable composition region A", "stable composition region B" and "stable composition region C" shown in the shaded area of ​​the phase diagram, wherein the composition is in the form of a solution, a suspension, an emulsion or a liquid mixture.

[0246] In another aspect of the above embodiment, the stable composition is described by "Stable Composition Region A", "Stable Composition Region B", and "Stable Composition Region C" shown in the shaded areas of the phase diagram, wherein the composition has a viscosity of about 20 cps to about 1000 cps and a density of about 0.8 gm / cm 3 to about 2gm / cm 3 .

[0247] In another aspect of the above embodiment, the stable composition is described by "Stable Composition Region A", "Stable Composition Region B" and "Stable Composition Region C" shown in the shaded area of ​​the phase diagram, wherein the transmittance of the composition is at least 40%.

[0248] In another aspect of the above embodiment, the stable composition is described by "Stable Composition Region A", "Stable Composition Region B" and "Stable Composition Region C" shown in the shaded area of ​​the phase diagram, wherein the pH of the composition is about 3 to about 7.

[0249] In some embodiments, the stable compositions are described by "Stable Composition Region A," "Stable Composition Region B," and "Stable Composition Region C" shown in the shaded regions of the phase diagram, wherein the compositions are stable in 900 ml of 0.01 N HCl with 0.5% sodium lauryl sulfate when tested in a USP Type 2 apparatus with a sinker at 50 rpm and 37°C.

[0250] c) release not less than 70% over a 10 minute period; or

[0251] a) Release not less than 80% over a 15 minute period.

[0252] In some embodiments, the stable composition is described by "Stable Composition Region A", "Stable Composition Region B", and "Stable Composition Region C" shown in the shaded areas of the phase diagram, wherein the AUC of the composition when orally administered to a human subject under fasting conditions is (0-15min) At least about 10 ng.h / ml.

[0253] In some embodiments, the stable composition is described by "Stable Composition Region A", "Stable Composition Region B", and "Stable Composition Region C" shown in the shaded areas of the phase diagram, wherein the AUC of the composition when orally administered to a human subject under fasting conditions is (0-15min) From about 10 ng.h / ml to about 80 ng.h / ml.

[0254] In some embodiments, the stable composition is described by "Stable Composition Region A", "Stable Composition Region B", and "Stable Composition Region C" shown in the shaded areas of the phase diagram, wherein the AUC of the composition when orally administered to a human subject under fasting conditions is (0-30min) At least about 80 ng.h / ml.

[0255] In some embodiments, the stable composition is described by "Stable Composition Region A", "Stable Composition Region B", and "Stable Composition Region C" shown in the shaded area of ​​the phase diagram, wherein the AUC of the composition when orally administered to a human subject under fasting conditions is (0-30min) From about 80 ng.h / ml to about 400 ng.h / ml.

[0256] In some embodiments, the stable composition is described by "Stable Composition Region A", "Stable Composition Region B", and "Stable Composition Region C" shown in the shaded areas of the phase diagram, wherein the AUC of the composition when orally administered to a human subject under fasting conditions is (0-1hr)At least about 400 ng.h / ml.

[0257] In some embodiments, the stable composition is described by "Stable Composition Region A", "Stable Composition Region B", and "Stable Composition Region C" shown in the shaded areas of the phase diagram, wherein the AUC of the composition when orally administered to a human subject under fasting conditions is (0-1hr) From about 400 ng.h / ml to about 1500 ng.h / ml.

[0258] In some embodiments, the stable composition is described by "Stable Composition Region A", "Stable Composition Region B", and "Stable Composition Region C" shown in the shaded areas of the phase diagram, wherein the AUC of the composition when orally administered to a human subject under fasting conditions is (0-2hr) At least about 1000 ng.h / ml.

[0259] In some embodiments, the stable composition is described by "Stable Composition Region A", "Stable Composition Region B", and "Stable Composition Region C" shown in the shaded areas of the phase diagram, wherein the AUC of the composition when orally administered to a human subject under fasting conditions is (0-2hr) From about 1000 ng.h / ml to about 4000 ng.h / ml.

[0260] In some embodiments, the stable composition is described by "Stable Composition Region A", "Stable Composition Region B", and "Stable Composition Region C" shown in the shaded areas of the phase diagram, wherein the AUC of the composition when orally administered to a human subject under fasting conditions is (0-t) At least about 2000 ng.h / ml.

[0261] In some embodiments, the stable composition is described by "Stable Composition Region A", "Stable Composition Region B", and "Stable Composition Region C" shown in the shaded areas of the phase diagram, wherein the AUC of the composition when orally administered to a human subject under fasting conditions is (0-∞) At least about 2000 ng.h / ml.

[0262] In some embodiments, the stable compositions are described by "Stable Composition Region A", "Stable Composition Region B", and "Stable Composition Region C" shown in the shaded regions of the phase diagram, wherein the compositions have a T of 100 when orally administered to a human subject under fasting conditions. lag No more than 8 minutes.

[0263] In some embodiments, the stable compositions are described by "Stable Composition Region A", "Stable Composition Region B", and "Stable Composition Region C" shown in the shaded regions of the phase diagram, wherein the compositions have a T of 100 when orally administered to a human subject under fasting conditions. max Less than about 90 minutes.

[0264] In some embodiments, the stable composition is described by "Stable Composition Region A", "Stable Composition Region B", and "Stable Composition Region C" shown in the shaded areas of the phase diagram, wherein the composition provides at least one of the following pharmacokinetic parameters when orally administered to a human subject under fasting conditions:

[0265] a) AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0266] b) AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0267] c) AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0268] d) AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0269] e) an AUC of at least about 2000 ng.h / mL (0-t) ;

[0270] f) an AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0271] g) T not exceeding 8 minutes lag .

[0272] In some embodiments, the stable composition is described by "Stable Composition Region A", "Stable Composition Region B", and "Stable Composition Region C" shown in the shaded areas of the phase diagram, wherein the composition comprises a reduced dose of celecoxib that provides at least one of the following pharmacokinetic parameters when orally administered to a human subject under fasting conditions:

[0273] a) AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0274] b) AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0275] c) AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0276] d) AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0277] e) an AUC of at least about 2000 ng.h / mL (0-t) ;

[0278] f) an AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0279] g) T not exceeding 8 minutes lag .

[0280] The stable oral liquid pharmaceutical compositions disclosed herein may comprise various average oil droplet sizes. In some embodiments, the average oil droplet size of the composition is no more than 500 nm, no more than 250 nm, no more than 100 nm, no more than 50 nm.

[0281] In some embodiments, the celecoxib composition of the present application is stable and does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C for at least 60 minutes under stirring at a speed of 50 rpm, and the average oil droplet size of the composition does not exceed 500 nm.

[0282] In some embodiments, the celecoxib composition of the present application is stable and does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C for at least 60 minutes under stirring at a speed of 50 rpm, and the average oil droplet size of the composition does not exceed 250 nm.

[0283] In some embodiments, the celecoxib composition of the present application is stable and does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C for at least 60 minutes under stirring at a speed of 50 rpm, and the average oil droplet size of the composition does not exceed 100 nm.

[0284] In some embodiments, the celecoxib composition of the present application is stable and does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C for at least 60 minutes under stirring at a speed of 50 rpm, and the average oil droplet size of the composition does not exceed 50 nm.

[0285] The stable oral liquid pharmaceutical compositions disclosed herein may comprise various viscosities. In some embodiments, the viscosity of the stable oral liquid composition of celecoxib of the present application is about 20cps, about 40cps, about 60cps, about 80cps, about 100cps, about 200cps, about 500cps, about 1000cps, or in the range between any two of the above values.

[0286] The stable oral liquid pharmaceutical compositions disclosed herein may comprise various densities. In some embodiments, the density of the stable oral liquid composition of celecoxib of the present application is about 0.8 gm / cm 3 to about 2gm / cm 3 .

[0287] In some embodiments, the average oil droplet size of the composition is no more than 500 nm, no more than 250 nm, no more than 100 nm, or no more than 50 nm.

[0288] In some embodiments, the stable oral liquid composition of the present invention has a viscosity of about 20 cps to about 1000 cps.

[0289] In some embodiments, the density of the stable oral liquid composition of the present application is about 0.8 gm / cm 3 to about 2gm / cm 3 .

[0290] In some embodiments, the stable oral liquid composition of the present application has a light transmittance of at least 40%.

[0291] In some embodiments, the pH of the stable oral liquid composition of the present application is from about 3 to about 7.

[0292] In some embodiments, the celecoxib composition of the present application further comprises water in an amount less than about 10% of the total weight of the composition.

[0293] The stable oral liquid pharmaceutical composition disclosed herein may include various transmittances. In some embodiments, the transmittance of the stable oral liquid composition of celecoxib of the present application is at least 40%. In some embodiments, the transmittance of the stable oral liquid composition of celecoxib of the present application is greater than 40%.

[0294] The stable oral liquid pharmaceutical compositions disclosed herein may comprise various pH values. In some embodiments, the pH of the stable oral liquid compositions of celecoxib of the present application is about 3 to about 7.

[0295] In some embodiments, the present application provides a stable oral liquid pharmaceutical composition of celecoxib, comprising:

[0296] a. a therapeutically effective amount of celecoxib;

[0297] b. at least one solubilizing agent in an amount of about 35% w / w to about 45% w / w;

[0298] c. at least one polar solvent in an amount of about 25% w / w to about 42% w / w; and

[0299] d. at least one pharmaceutically acceptable excipient,

[0300] wherein the solubilizer and the polar solvent are present in a weight ratio of about 0.60:1.00 to about 1.8:1.00, and wherein the composition has a viscosity of about 20 cps to about 1000 cps and a density of about 0.8 gm / cm 3 to about 2gm / cm 3 .

[0301] Improved stability

[0302] In some embodiments, the present application relates to a composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, and at least one pharmaceutically acceptable excipient, wherein the composition does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C for at least 60 minutes under stirring at a speed of 50 rpm.

[0303] In some embodiments, the stable oral liquid compositions of celecoxib of the present application are substantially free of precipitation inhibitors, such as polyoxyethylene-polyoxypropylene block copolymers, pluronics, polyvinyl pyrrolidone, hydroxypropyl cellulose, and hydroxypropyl methylcellulose.

[0304] In some embodiments, the present application provides a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, and at least one pharmaceutically acceptable excipient, wherein the composition does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C when measured at a time point of 30 min, 60 min, 90 min, 120 min, 180 min, or 240 min under stirring at a speed of 50 rpm; and the composition is substantially free of precipitation inhibitors, such as polyoxyethylene-polyoxypropylene block copolymers, pluronics, polyvinyl pyrrolidone, hydroxypropyl cellulose, and hydroxypropyl methylcellulose.

[0305] In some embodiments, the present application provides a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, and at least one pharmaceutically acceptable excipient, wherein the composition does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C when measured at a time point of 30 min, 60 min, 90 min, 120 min, 180 min, or 240 min under stirring at a speed of 50 rpm; and the composition is substantially free of precipitation inhibitors, for example, polyoxyethylene-polyoxypropylene block copolymers, pluronics, polyvinyl pyrrolidone, hydroxypropyl cellulose, and hydroxypropyl methylcellulose.

[0306] In some embodiments, the average oil droplet size of the composition is no more than 500 nm, no more than 250 nm, no more than 100 nm, or no more than 50 nm.

[0307] In some embodiments, the stable oral liquid compositions of the present invention have a viscosity of about 20 cps to about 1000 cps.

[0308] In some embodiments, the stable oral liquid composition of the present application has a density of about 0.8 gm / cm 3 to about 2gm / cm 3 .

[0309] In some embodiments, the stable oral liquid composition of the present application has a light transmittance of at least 40%.

[0310] In some embodiments, the pH of the stable oral liquid compositions of the present application is from about 3 to about 7.

[0311] In some embodiments, the present application provides a stable oral liquid pharmaceutical composition of celecoxib, comprising:

[0312] a. a therapeutically effective amount of celecoxib;

[0313] b. at least one solubilizing agent in an amount of about 35% w / w to about 45% w / w;

[0314] c. at least one polar solvent in an amount of about 25% w / w to about 42% w / w; and

[0315] d. at least one pharmaceutically acceptable excipient,

[0316] The solubilizer and the polar solvent are present in a weight ratio of about 0.60:1.00 to about 1.8:1.00, and do not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C±0.5°C for at least 60 minutes under stirring at a speed of 50 rpm.

[0317] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer and at least one medium-chain glyceride, wherein the composition does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C for at least 60 minutes under stirring at a speed of 50 rpm.

[0318] In some embodiments, the present application relates to a composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer and at least one pharmaceutically acceptable excipient, wherein the composition does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C for at least 60 minutes under stirring at a speed of 50 rpm.

[0319] In some embodiments, the present application provides a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer and at least one pharmaceutically acceptable excipient, wherein the composition does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C when measured at a time point of 30 min, 60 min, 90 min, 120 min, 180 min or 240 min under stirring at a speed of 50 rpm; and the composition is substantially free of precipitation inhibitors, such as polyoxyethylene-polyoxypropylene block copolymers, pluronics, polyvinyl pyrrolidone, hydroxypropyl cellulose and hydroxypropyl methylcellulose.

[0320] In some embodiments, the present application provides a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer and at least one pharmaceutically acceptable excipient, wherein the composition does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C when measured at a time point of 30 min, 60 min, 90 min, 120 min, 180 min or 240 min under stirring at a speed of 50 rpm; and the composition is substantially free of precipitation inhibitors, such as polyoxyethylene-polyoxypropylene block copolymers, pluronics, polyvinyl pyrrolidone, hydroxypropyl cellulose and hydroxypropyl methylcellulose.

[0321] In some embodiments, the present application provides a pharmaceutical composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C for at least 60 minutes under stirring at a speed of 50 rpm.

[0322] In some embodiments, the present application provides a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C when measured at a time point of 30 min, 60 min, 90 min, 120 min, 180 min, or 240 min under stirring at a speed of 50 rpm; and the composition is substantially free of precipitation inhibitors, such as polyoxyethylene-polyoxypropylene block copolymers, pluronics, polyvinyl pyrrolidone, hydroxypropyl cellulose, and hydroxypropyl methylcellulose.

[0323] In some embodiments, the present application provides a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C when measured at a time point of 30 min, 60 min, 90 min, 120 min, 180 min, or 240 min under stirring at a speed of 50 rpm; and the composition is substantially free of precipitation inhibitors, such as polyoxyethylene-polyoxypropylene block copolymers, pluronics, polyvinyl pyrrolidone, hydroxypropyl cellulose, and hydroxypropyl methylcellulose.

[0324] In some embodiments, the viscosity of the oral liquid composition of the present application is from about 20 cps to about 1000 cps.

[0325] In some embodiments, the density of the oral liquid composition of the present application is about 0.8 gm / cm 3 to about 2gm / cm 3 .

[0326] In some embodiments, the celecoxib composition of the present application does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at pH 2.0 and temperature 37°C ± 0.5°C for at least 240 minutes under stirring at a speed of 50 rpm.

[0327] In some embodiments, the celecoxib compositions of the present application are substantially free of precipitation inhibitors, such as polyoxyethylene-polyoxypropylene block copolymers, pluronics, polyvinylpyrrolidone, hydroxypropylcellulose, and hydroxypropylmethylcellulose.

[0328] In some embodiments, the present application provides a composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent and at least one pharmaceutically acceptable excipient; wherein when subjected to fasting simulated gastric fluid (FaSSGF) with a pH of 2.0 and a temperature of 37°C ± 0.5°C under stirring at a speed of 50 rpm, the average oil droplet size of the composition does not exceed 500 nm when measured at a time point of 30 min, 60 min, 90 min, 120 min, 180 min or 240 min.

[0329] In some embodiments, the celecoxib composition of the present application comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium-chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C for at least 240 minutes under stirring at a speed of 50 rpm.

[0330] Reduced dose

[0331] It is observed that the oral liquid composition of celecoxib of the present application is different from conventional celecoxib compositions (such as Compared with oral capsules, it showed increased bioavailability (AUC( 0-15min )、AUC( 0-30min )、AUC( 0-1小时 )、AUC( 0-2小时 )), and need less dosage. Therefore, need such oral composition, it has the celecoxib of lower dosage or reduced dosage, the celecoxib of described lower dosage or reduced dosage can realize the same or better therapeutic effect compared with the observed therapeutic effect of the conventional celecoxib composition with larger dosage, so that the side effect of celecoxib is minimized.

[0332] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the reduced dose of celecoxib provides a similar effect to conventional celecoxib compositions (such as Oral capsules) have the same or better therapeutic effect than oral capsules.

[0333] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the reduced dose of celecoxib provides a conventional celecoxib composition (such as Oral capsules) with similar or higher AUC (0-15min) , AUC (0-30min) , AUC (0-1小时) and AUC (0-2小时) .

[0334] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the reduction in the dose of celecoxib is compared to a conventional celecoxib composition (such as Oral capsules) by at least 20%.

[0335] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the reduction in the dose of celecoxib is compared to a conventional celecoxib composition (such as Oral capsules) by at least 30%.

[0336] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the reduction in the dose of celecoxib is compared to a conventional celecoxib composition (such as Oral capsules) by at least 40%.

[0337] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the reduction in the dose of celecoxib is compared to a conventional celecoxib composition (such as Oral capsules) by at least 50%.

[0338] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the reduction in the dose of celecoxib is compared to a conventional celecoxib composition (such as Oral capsules) by at least 60%.

[0339] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the reduction in the dose of celecoxib is compared to a conventional celecoxib composition (such as Oral capsules) by at least 70%.

[0340] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the reduction in the dose of celecoxib is compared to a conventional celecoxib composition (such as Oral capsules) by at least 80%.

[0341] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the reduction in the dose of celecoxib is compared to a conventional celecoxib composition comprising 400 mg of celecoxib (such as 400 mg oral capsule) by at least 40%.

[0342] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the reduction in the dose of celecoxib is compared to a conventional celecoxib composition comprising 400 mg of celecoxib (such as 400 mg oral capsule) by at least 55%.

[0343] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the reduction in the dose of celecoxib is compared to a conventional celecoxib composition comprising 400 mg of celecoxib (such as 400 mg oral capsule) by at least 70%.

[0344] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the reduced dose is about 100 mg to 250 mg of celecoxib.

[0345] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the reduced dose is about 240 mg.

[0346] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the reduced dose is about 180 mg.

[0347] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the reduced dose is about 120 mg.

[0348] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the reduction in the dose of celecoxib is compared to a conventional celecoxib composition comprising 400 mg of celecoxib (such as 400 mg oral capsule) by at least 70%.

[0349] In some embodiments, the celecoxib composition of the present application comprises a reduced dose of celecoxib, wherein the reduced dose is about 100 mg to 250 mg of celecoxib.

[0350] In some embodiments, the celecoxib compositions of the present application are substantially free of precipitation inhibitors, such as polyoxyethylene-polyoxypropylene block copolymers, pluronics, polyvinylpyrrolidone, hydroxypropylcellulose, and hydroxypropylmethylcellulose.

[0351] In some embodiments, the present application provides an oral liquid pharmaceutical composition comprising a reduced dose of celecoxib, at least one solubilizer, at least one medium chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the reduced dose comprises about 100 mg to 250 mg of celecoxib, wherein the composition provides at least one of the following pharmacokinetic parameters when orally administered to a human subject under fasting conditions:

[0352] a) AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0353] b) AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0354] c) AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0355] d) AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0356] e) an AUC of at least about 2000 ng.h / mL (0-t) ;

[0357] f) an AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0358] g) T not exceeding 8 minutes lag .

[0359] In some embodiments, the present application provides an oral liquid pharmaceutical composition comprising a reduced dose of celecoxib, at least one solubilizer, at least one medium chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the reduced dose comprises about 100 mg to 250 mg of celecoxib, wherein the composition comprises the solubilizer and the polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00, and provides at least one of the following pharmacokinetic parameters when orally administered to a human subject under fasting conditions:

[0360] a) AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0361] b) AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0362] c) AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0363] d) AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0364] e) an AUC of at least about 2000 ng.h / mL (0-t) ;

[0365] f) an AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0366] g) T not exceeding 8 minutes lag .

[0367] In some embodiments, the present application provides an oral liquid pharmaceutical composition of celecoxib, wherein the composition comprises about 100 mg to 250 mg of celecoxib, at least one solubilizer, at least one medium chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition comprises the solubilizer and the polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00, and provides at least one of the following pharmacokinetic parameters when orally administered to a human subject under fasting conditions:

[0368] a) AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0369] b) AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0370] c) AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0371] d) AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0372] e) an AUC of at least about 2000 ng.h / mL (0-t) ;

[0373] f) an AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0374] g) T not exceeding 8 minutes lag .

[0375] Pharmaceutically acceptable excipients, flavoring agents and sweeteners

[0376] In some embodiments, the celecoxib composition of the present application may further comprise at least one flavoring agent or taste masking agent. These flavoring agents or taste masking agents are well known in the art or are approved by the US FDA.

[0377] A non-limiting exemplary list of flavoring / taste masking agents is: natural or synthetic flavoring liquids such as volatile oils, synthetic flavor oils, flavoring spice oils, liquids obtained from plants, leaves, flowers, fruits, stems, and combinations thereof, oleoresins or extracts. Non-limiting representative examples of volatile oils include spearmint oil, cinnamon oil, wintergreen oil (methyl salicylate), peppermint oil, menthol, clove oil, bay oil, anise oil, eucalyptus oil, thyme oil, cedar leaf oil, nutmeg oil, allspice oil, sage oil, mace extract, bitter almond oil, and cassia oil. In addition, artificial, natural or synthetic flavors include fruit flavors such as vanilla, and citrus oils, including lemon, orange, grape, lemon and grapefruit, and fruit flavors, including apple, pear, peach, grape, strawberry, raspberry, cherry, plum, pineapple, apricot, banana, other useful flavoring agents include aldehydes and esters, such as benzaldehyde (cherry, almond), citral (lemon, lemon), neral (i.e., β-citral (lemon, lemon)), decanal (orange, lemon), C-8 aldehydes (citrus fruits), C-9 aldehydes (citrus fruits), C-12 aldehydes (citrus fruits), tolyl aldehyde (cherry, almond), 2,6-dimethyloctanal (unripe fruits), and 2-dodecenal (citrus, orange), bubble gum flavor, mixtures thereof, etc.

[0378] A non-limiting exemplary list of sweeteners is: sugars such as sucrose, glucose (corn syrup), dextrose, invert sugar, fructose and mixtures thereof, saccharin and its various salts, e.g., sodium or calcium salts; cyclohexylaminosulfonic acid and its various salts, e.g., sodium salt; dipeptide sweeteners such as aspartame, acesulfame K; and other sweeteners, such as magnasweet, sucralose, mixtures thereof, and the like.

[0379] Ways to treat pain

[0380] In some embodiments, the present application relates to a method for treating pain in a human subject by oral administration of a stable oral liquid pharmaceutical composition disclosed herein. In some embodiments, the composition comprises a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium chain glyceride, and at least one pharmaceutically acceptable excipient, wherein the composition does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at pH 2.0 and temperature 37°C ± 0.5°C for at least 60 minutes under stirring at a speed of 50 rpm.

[0381] In some embodiments, the present application relates to a method for treating pain in a human individual by oral administration of a composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one polar solvent, at least one medium-chain glyceride, and at least one pharmaceutically acceptable excipient, wherein the composition does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at a pH of 2.0 and a temperature of 37°C ± 0.5°C for at least 60 minutes under stirring at a speed of 50 rpm.

[0382] In some embodiments, the average oil droplet size of the composition is no more than 1000 nm, no more than 500 nm, no more than 250 nm, no more than 100 nm, or no more than 50 nm.

[0383] In some embodiments, the present application relates to a method for treating pain in a human subject by oral administration of a composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition comprises the solubilizer and the polar solvent in a weight ratio of about 0.60:1.00 to about 1.8:1.00.

[0384] In some embodiments, the present application relates to a method of treating pain in a human subject by oral administration of a composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein the composition is substantially free of precipitation inhibitors, such as polyoxyethylene-polyoxypropylene block copolymers, pluronics, polyvinyl pyrrolidone, hydroxypropyl cellulose, and hydroxypropyl methylcellulose.

[0385] In some embodiments, the present application relates to a method of treating pain in a human subject by oral administration of a composition comprising a therapeutically effective amount of celecoxib, wherein the composition has a light transmittance of at least 40%.

[0386] In some embodiments, the present application relates to a method of treating pain in a human subject by oral administration of a composition comprising a therapeutically effective amount of celecoxib, wherein the pH of the composition is about 3 to about 7.

[0387] In some embodiments, the present application relates to a method of treating pain in a human subject by administering an oral liquid pharmaceutical composition of celecoxib, the composition comprising:

[0388] a) a therapeutically effective amount of celecoxib;

[0389] b) at least one solubilizing agent in an amount of about 35% w / w to about 45% w / w; and

[0390] c) at least one polar solvent in an amount of about 25% w / w to about 42% w / w;

[0391] d) at least one pharmaceutically acceptable excipient;

[0392] wherein the solubilizer and the polar solvent are present in a weight ratio of about 0.60:1.00 to about 1.8:1.00, and wherein the composition has a viscosity of about 20 cps to about 1000 cps and a density of about 0.8 gm / cm 3 to about 2gm / cm 3 .

[0393] In some embodiments, the present application relates to a method of treating pain in a human subject by administering an oral liquid pharmaceutical composition of celecoxib, the composition comprising:

[0394] a) a reduced dose of celecoxib, wherein the reduction in the dose of celecoxib is at least 20% compared to a conventional celecoxib composition;

[0395] b) at least one solubilizing agent in an amount of about 35% w / w to about 45% w / w; and

[0396] c) at least one polar solvent in an amount of about 25% w / w to about 42% w / w;

[0397] d) at least one pharmaceutically acceptable excipient;

[0398] wherein the solubilizer and the polar solvent are present in a weight ratio of about 0.60:1.00 to about 1.8:1.00, and wherein the composition has a viscosity of about 20 cps to about 1000 cps and a density of about 0.8 gm / cm 3 to about 2gm / cm 3 .

[0399] In some embodiments, the present application relates to a method of treating pain in a human subject by administering an oral liquid pharmaceutical composition of celecoxib, wherein the composition provides at least one of the following pharmacokinetic parameters when orally administered to a human subject under fasting conditions:

[0400] a) AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0401] b) AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0402] c) AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0403] d) AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0404] e) an AUC of at least about 2000 ng.h / mL (0-t) ;

[0405] f) an AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0406] g) T not exceeding 8 minutes lag .

[0407] In some embodiments, the present application relates to a method of providing pain relief to a human subject suffering from pain by administering an oral liquid pharmaceutical composition of celecoxib, wherein the composition provides at least one of the following pharmacokinetic parameters when orally administered to a human subject under fasting conditions:

[0408] a) AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0409] b) AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0410] c) AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0411] d) AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0412] e) an AUC of at least about 2000 ng.h / mL (0-t) ;

[0413] f) an AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0414] g) T not exceeding 8 minutes lag .

[0415] In some embodiments, the present application relates to a method of providing pain relief to a human subject suffering from pain, the method comprising administering to the subject a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib and at least one pharmaceutically acceptable excipient, thereby providing pain relief to the subject 2 hours after administration, wherein the composition provides at least one of the following pharmacokinetic parameters when orally administered to a human subject under fasting conditions:

[0416] a) AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0417] b) AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0418] c) AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0419] d) AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0420] e) an AUC of at least about 2000 ng.h / mL (0-t) ;

[0421] f) an AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0422] g) T not exceeding 8 minutes lag .

[0423] In some embodiments, the present application relates to a method of providing partial pain relief to a human subject suffering from pain, the method comprising administering to the subject a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium chain glyceride, and at least one pharmaceutically acceptable excipient, thereby providing pain relief to the subject within less than about 2 hours after administration, wherein the composition provides at least one of the following pharmacokinetic parameters when orally administered to a human subject under fasting conditions:

[0424] a) AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0425] b) AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0426] c) AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0427] d) AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0428] e) an AUC of at least about 2000 ng.h / mL (0-t) ;

[0429] f) an AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0430] g) T not exceeding 8 minutes lag .

[0431] In some embodiments, the present application relates to a method of providing partial pain relief in less than about 2 hours to a human subject suffering from pain by administering an oral pharmaceutical composition of celecoxib, wherein the composition provides at least one of the following pharmacokinetic parameters when orally administered to a human subject under fasting conditions:

[0432] a) AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0433] b) AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0434] c) AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0435] d) AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0436] e) an AUC of at least about 2000 ng.h / mL (0-t) ;

[0437] f) an AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0438] g) T not exceeding 8 minutes lag .

[0439] In some embodiments, the present application relates to a method of reducing the most bothersome symptoms in a human subject suffering from migraine by administering an oral pharmaceutical composition of celecoxib, wherein the composition provides at least one of the following pharmacokinetic parameters when orally administered to the human subject under fasting conditions:

[0440] a) AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0441] b) AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0442] c) AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0443] d) AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0444] e) an AUC of at least about 2000 ng.h / mL (0-t) ;

[0445] f) an AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0446] g) T not exceeding 8 minutes lag .

[0447] In some embodiments, the present application is directed to a method of reducing the most bothersome symptom in a human subject suffering from migraine, the method comprising administering to the subject a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib and at least one pharmaceutically acceptable excipient, thereby providing a reduction in the most bothersome symptom to the subject, wherein the composition provides at least one of the following pharmacokinetic parameters when orally administered to the human subject under fasting conditions:

[0448] a) AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0449] b) AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0450] c) AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0451] d) AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0452] e) an AUC of at least about 2000 ng.h / mL (0-t) ;

[0453] f) an AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0454] g) T not exceeding 8 minutes lag .

[0455] In some embodiments, the present application relates to a method of providing pain relief to a human subject suffering from pain by administering an oral liquid pharmaceutical composition of celecoxib, wherein the composition provides at least one of the following pharmacokinetic parameters when orally administered to a human subject under fasting conditions:

[0456] a) AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0457] b) AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0458] c) AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0459] d) AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0460] e) an AUC of at least about 2000 ng.h / mL (0-t) ;

[0461] f) an AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0462] g) T not exceeding 8 minutes lag .

[0463] In some embodiments, the present application relates to a method for providing pain relief to a human subject suffering from pain, the method comprising administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib and at least one pharmaceutically acceptable excipient, thereby providing pain relief to the subject 2 hours after administration, wherein the composition provides at least one of the following pharmacokinetic parameters when orally administered to a human subject under fasting conditions:

[0464] a) AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0465] b) AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0466] c) AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0467] d) AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0468] e) an AUC of at least about 2000 ng.h / mL (0-t) ;

[0469] f) an AUC of at least about 2000 ng.h / mL(0-∞) ;as well as

[0470] g) T not exceeding 8 minutes lag .

[0471] In some embodiments, the present application relates to a method of providing partial pain relief in less than about 2 hours to a human subject suffering from pain by administering an oral liquid pharmaceutical composition of celecoxib, wherein the composition provides at least one of the following pharmacokinetic parameters when orally administered to a human subject under fasting conditions:

[0472] a) AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0473] b) AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0474] c) AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0475] d) AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0476] e) an AUC of at least about 2000 ng.h / mL (0-t) ;

[0477] f) an AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0478] g) T not exceeding 8 minutes lag .

[0479] In some embodiments, the present application relates to a method for providing partial pain relief to a human subject suffering from pain, the method comprising administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one medium chain glyceride, and at least one pharmaceutically acceptable excipient, thereby providing pain relief to the subject within less than about 2 hours after administration, wherein the composition provides at least one of the following pharmacokinetic parameters when orally administered to a human subject under fasting conditions:

[0480] a) AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0481] b) AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0482] c) AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0483] d) AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0484] e) an AUC of at least about 2000 ng.h / mL (0-t) ;

[0485] f) an AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0486] g) T not exceeding 8 minutes lag .

[0487] In some embodiments, the present application relates to a method of reducing the most bothersome symptoms in a human subject suffering from migraine by administering an oral liquid pharmaceutical composition of celecoxib, wherein the composition provides at least one of the following pharmacokinetic parameters when orally administered to a human subject under fasting conditions:

[0488] a) AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0489] b) AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0490] c) AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0491] d) AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0492] e) an AUC of at least about 2000 ng.h / mL (0-t) ;

[0493] f) an AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0494] g) T not exceeding 8 minutes lag .

[0495] In some embodiments, the present application is directed to a method for reducing the most bothersome symptom in a human subject suffering from migraine, the method comprising administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib and at least one pharmaceutically acceptable excipient, thereby providing a reduction in the most bothersome symptom to the subject, wherein the composition provides at least one of the following pharmacokinetic parameters when orally administered to the human subject under fasting conditions:

[0496] a) AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ;

[0497] b) AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ;

[0498] c) AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ;

[0499] d) AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ;

[0500] e) an AUC of at least about 2000 ng.h / mL (0-t) ;

[0501] f) an AUC of at least about 2000 ng.h / mL (0-∞) ;as well as

[0502] g) T not exceeding 8 minutes lag .

[0503] In some embodiments, the present application relates to methods for treating pain in a human subject by oral administration of a composition comprising a therapeutically effective amount of celecoxib, wherein the composition has a light transmittance of at least 40%.

[0504] In some embodiments, the present application relates to methods for treating pain in a human subject by oral administration of a composition comprising a therapeutically effective amount of celecoxib, wherein the pH of the composition is about 3 to about 7.

[0505] In some embodiments, the composition of the present application is used to treat or improve pain, including but not limited to: acute pain, migraine, cluster headache, neuropathic pain, postoperative pain, chronic low back pain, herpes neuralgia, phantom limb pain, central pain, dental pain, neuropathic pain, opioid-resistant pain, visceral pain, surgical pain, bone injury pain, arthritis pain, inflammatory pain, osteoarthritis pain, juvenile rheumatoid arthritis pain, ankylosing spondylitis pain, primary dysmenorrhea pain, pain during labor and delivery, pain caused by burns (including sunburn), postpartum pain, angina pectoris, genital urinary tract related pain (including cystitis), breakthrough pain or any type of cancer pain. The term should also refer to nociceptive pain or nociception in patients in need.

[0506] Treatments for migraines

[0507] In some embodiments, the present application relates to a method for providing pain relief to a human subject suffering from pain, the method comprising administering to the subject a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib and at least one pharmaceutically acceptable excipient, thereby providing pain relief to the subject 2 hours after administration. In some embodiments, the present application relates to a method for treating migraine in a human subject by oral administration of a stable oral liquid pharmaceutical composition disclosed herein. In some embodiments disclosed herein, the method for providing pain relief to a human subject suffering from pain comprises administering to the subject a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib. In some embodiments disclosed herein, the method for providing pain relief to a human subject suffering from pain comprises administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib. In some embodiments disclosed herein, the method for providing pain relief to a human subject suffering from pain at 2 hours comprises administering to the subject a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib. In some embodiments disclosed herein, a method for providing pain relief at 2 hours to a human subject suffering from pain comprises administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib.

[0508] In some embodiments, the present application relates to a method for providing partial pain relief to a human subject suffering from pain, the method comprising administering to the subject a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib and at least one pharmaceutically acceptable excipient, thereby providing pain relief to the subject within less than about 2 hours after administration. In some embodiments, the method for providing partial pain relief to a human subject suffering from pain within less than about 2 hours after administration comprises administering to the subject a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib. In some embodiments, the method for providing partial pain relief to a human subject suffering from pain within less than about 2 hours comprises administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib. In some embodiments, the method results in at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35% or more of the treated human subject eliminating pain at 2 hours. In some embodiments, the method results in an increase in the percentage of treated human subjects who are pain free at 2 hours by at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or more compared to the percentage of human subjects treated with a placebo. In some embodiments, the method results in at least 45%, at least 50%, at least 60%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75% or more partial pain relief in treated human subjects at 2 hours. In some embodiments, the methods result in an increase in the percentage of treated human subjects with partial relief of pain at 2 hours by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70% or more, compared to the percentage of human subjects treated with a placebo.

[0509] In some embodiments, the present application relates to a method for treating migraine headaches in a human individual by orally administering a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib to the human individual. In some embodiments, the method results in at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35% or more of the treated human individuals eliminating pain at 2 hours. In some embodiments, the method results in an increase in the percentage of treated human individuals who eliminate pain at 2 hours compared to the percentage of human individuals treated with a placebo, and the increase is at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or more. In some embodiments, the methods result in at least 45%, at least 50%, at least 60%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75% or more partial pain relief in treated human subjects at 2 hours. In some embodiments, the methods result in an increase in the percentage of treated human subjects with partial pain relief at 2 hours compared to the percentage of human subjects treated with a placebo by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70% or more.

[0510] In some embodiments, a method for providing partial pain relief to a human subject with pain in less than about 2 hours comprises administering to the subject a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib, wherein the partial pain relief is maintained for at least about 4 hours. In some embodiments, a method for providing partial pain relief to a human subject with pain in less than about 2 hours comprises administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, wherein the partial pain relief is maintained for at least about 4 hours. In some embodiments, a method for providing partial pain relief to a human subject with pain in less than about 2 hours comprises administering to the subject a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib, wherein the partial pain relief refers to a pain intensity reported by the human subject with pain according to a numeric rating scale for pain ranging from 0 (no pain) to 3 (severe pain) that is ≥1 level lower than the rating before administration. In some embodiments, a method for providing partial pain relief to a human subject suffering from pain in less than about 2 hours comprises administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, wherein the partial pain relief means that the pain intensity reported by the human subject suffering from pain is ≥ 1 level lower than the rating before administration on a numeric rating scale for pain ranging from 0 (no pain) to 3 (severe pain).

[0511] In some embodiments, the application relates to methods comprising administering a composition disclosed herein resulting in at least 26%, at least 27%, at least 28%, at least 29%, or at least 30% of the treated human subjects being pain free at 2 hours.

[0512] In some embodiments, the application relates to methods comprising administering a composition disclosed herein resulting in partial pain relief in at least 63% of the treated human subjects at 2 hours.

[0513] In some embodiments, the methods of using the stable oral liquid pharmaceutical compositions disclosed herein result in an increase in the percentage of treated human subjects who are pain free at 2 hours by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or more compared to the percentage of human subjects treated with commercially available migraine treatments (e.g., VIOXX 25 (25 mg), VIOXX 50 (50 mg), and CAMBIA 50 (50 mg)). In some embodiments, the methods result in an increase in the percentage of treated human subjects with partial pain relief at 2 hours by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70% or more compared to the percentage of human subjects treated with commercially available migraine treatments (e.g., VIOXX 25 (25 mg), VIOXX 50 (50 mg), and CAMBIA 50 (50 mg)). In some embodiments, the methods result in an increase in the percentage of treated human subjects who are pain free at 2 hours by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or more compared to the percentage of human subjects treated with commercially available migraine treatments (e.g., VIOXX 25 (25 mg), VIOXX 50 (50 mg), and CAMBIA 50 (50 mg)).

[0514] In some embodiments, the methods comprising administering a composition disclosed herein result in an increase in the percentage of treated human subjects who are pain free at 2 hours by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or more compared to the percentage of human subjects treated with commercially available migraine treatments (e.g., VIOXX 25 (25 mg), VIOXX 50 (50 mg), and CAMBIA 50 (50 mg)).

[0515] Some embodiments disclosed herein provide a method for treating pain in a human subject, the method comprising administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one polar solvent, at least one medium-chain glyceride, and at least one pharmaceutically acceptable excipient, wherein the stable oral liquid pharmaceutical composition is substantially free of a precipitation inhibitor, wherein the therapeutically effective amount of celecoxib is sufficient to relieve the subject of pain for at least 4 hours, at least 6 hours, at least 8 hours, at least 10 hours, at least 12 hours, at least 16 hours, at least 18 hours, at least 24 hours, at least 48 hours, or more after administration of the stable oral liquid pharmaceutical composition. In some embodiments, the stable oral liquid pharmaceutical composition comprises a therapeutically effective amount of celecoxib, at least one solubilizer in an amount of about 35% w / w to about 45% w / w, at least one polar solvent in an amount of about 25% w / w to about 42% w / w, at least one medium-chain glyceride, and at least one pharmaceutically acceptable excipient, wherein the stable oral liquid pharmaceutical composition is substantially free of a precipitation inhibitor. In some embodiments, the pain is associated with migraine. In some embodiments, the therapeutically effective amount of celecoxib is sufficient to eliminate pain in the individual within 2 hours after administration of the stable oral liquid pharmaceutical composition. In some embodiments, the therapeutically effective amount of celecoxib is sufficient to provide partial pain relief to the individual within 2 hours after administration of the stable oral liquid pharmaceutical composition. In some embodiments, administration of the stable oral liquid pharmaceutical composition results in at least 25% of the treated human individuals being pain-free for at least 24 hours after treatment. In some embodiments, administration of the stable oral liquid pharmaceutical composition results in at least 45% of the treated human individuals being pain-free for at least 24 hours after treatment. In some embodiments, administration of the stable oral liquid pharmaceutical composition results in an increase of at least 40% in the percentage of treated human individuals who are pain-free for at least 24 hours after treatment compared to the percentage of human individuals treated with a placebo. In some embodiments, administration of the stable oral liquid pharmaceutical composition results in an increase of at least 10% in the percentage of treated human subjects who are pain free for at least 24 hours after treatment compared to the percentage of human subjects treated with commercially available migraine treatments (e.g., VIOXX 25 (25 mg), VIOXX 50 (50 mg), and CAMBIA 50 (50 mg)). In some embodiments disclosed herein, a method for providing pain relief to a human subject suffering from pain comprises administering to the subject a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib, wherein the pain relief is maintained for at least about 2 hours to about 24 hours.In some embodiments disclosed herein, a method for providing pain relief to a human subject suffering from pain comprises administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, wherein the pain relief is maintained for at least about 2 hours to about 24 hours.

[0516] In some embodiments, the present application relates to a method for reducing the most bothersome symptom in a human subject suffering from migraine, the method comprising administering to the subject a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib and at least one pharmaceutically acceptable excipient, thereby providing the subject with a reduction in the most bothersome symptom. In some embodiments disclosed herein, a method for treating pain in a human subject is provided, the method comprising administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, at least one solubilizer, at least one polar solvent, at least one medium chain glyceride, and at least one pharmaceutically acceptable excipient, wherein the stable oral liquid pharmaceutical composition is substantially free of a precipitation inhibitor, wherein the therapeutically effective amount of celecoxib is sufficient to eliminate the most bothersome symptom, such as nausea, phonophobia, and photophobia, within 10 min, 20 min, 30 min, 60 min, within 2 hours, within 4 hours, within 6 hours, within 12 hours after administration of the stable oral liquid pharmaceutical composition. In some embodiments, the method for reducing the most bothersome symptom in a human subject suffering from migraine comprises administering to the subject a stable oral pharmaceutical composition comprising a therapeutically effective amount of celecoxib, wherein the most bothersome symptom is reduced within about 2 hours after administration of the composition. In some embodiments, the method for reducing the most bothersome symptom in a human subject suffering from migraine comprises administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib, wherein the most bothersome symptom is reduced within about 2 hours after administration of the composition. In some embodiments, the stable oral liquid pharmaceutical composition comprises a therapeutically effective amount of celecoxib, at least one solubilizer in an amount of about 35% w / w to about 45% w / w, at least one polar solvent in an amount of about 25% w / w to about 42% w / w, at least one medium chain glyceride, and at least one pharmaceutically acceptable excipient, wherein the stable oral liquid pharmaceutical composition is substantially free of a precipitation inhibitor. In some embodiments, the pain is associated with migraine. In some embodiments, the therapeutically effective amount of celecoxib is sufficient to eliminate pain in the subject within 2 hours after administration of the stable oral liquid pharmaceutical composition. In some embodiments, the therapeutically effective amount of celecoxib is sufficient to provide partial pain relief to the individual within 2 hours after administration of the stable oral liquid pharmaceutical composition. In some embodiments, administration of the stable oral liquid pharmaceutical composition results in at least 25% of the treated human subjects eliminating the most bothersome symptom within 2 hours after treatment. In some embodiments, administration of the stable oral liquid pharmaceutical composition results in at least 45% of the treated human subjects eliminating the most bothersome symptom within 2 hours after treatment.In some embodiments, administration of the stable oral liquid pharmaceutical composition results in an increase of at least 40% in the percentage of human subjects treated with placebo who have eliminated the most bothersome symptom within 2 hours after treatment compared to the percentage of human subjects treated with placebo. In some embodiments, administration of the stable oral liquid pharmaceutical composition results in an increase of at least 10% in the percentage of human subjects treated with commercially available migraine therapeutic agents (e.g., VIOXX 25 (25 mg), VIOXX 50 (50 mg), and CAMBIA 50 (50 mg)) who have eliminated the most bothersome symptom within 2 hours after treatment compared to the percentage of human subjects treated with commercially available migraine therapeutic agents (e.g., VIOXX 25 (25 mg), VIOXX 50 (50 mg), and CAMBIA 50 (50 mg)).

[0517] Some embodiments of the methods described herein also include obtaining a report from the individual after administration. The report can be, for example, a report of pain levels after administration. This pain level can be compared with the pain level reported by the individual before administration, and in this regard, some embodiments of the methods also include obtaining a report from the individual before administration. In addition to the report of pain levels after administration, other examples of reports that can be obtained from the individual after administration include the time point of pain relief, the time point of pain elimination, the time point of eliminating the most annoying symptoms, the time period of keeping pain relief, the time period of keeping pain elimination, and the time period of keeping eliminating the most annoying symptoms.

[0518] In some embodiments, the oral liquid composition of the present application can be distributed in the form of a liquid packaged in a bottle or any other suitable container for oral administration. Before oral administration, the liquid composition can be taken with or without further mixing with an aqueous or suitable medium.

[0519] In some embodiments, the oral liquid compositions of the present application can be dispensed in containers such as sachets, ampoules, syringes, dropper devices, tubes or bottles (e.g., tubes or bottles that can be squeezed to deliver their contents), optionally as fixed doses, the contents of which can be directly orally ingested or mixed or dispersed into food or liquids.

[0520] In some embodiments, the composition of the present application can be formulated into capsules suitable for oral administration. The composition can be filled in hard gelatin capsules or soft gelatin capsules, HPMC capsules or capsules made of any other pharmaceutically acceptable materials.

[0521] In some embodiments, the compositions of the present application can be sprayed onto an inert substrate, which can be a powder or multiparticulates, such as granules, pellets, beads, spheres, beads, microcapsules, microspheres, nanocapsules, nanospheres, or microspheres.

[0522] The matrix constitutes a finely divided (ground, micronized, nanosized, precipitated) form of inert additive molecular aggregates or a complex aggregate of multiple components, or a physical mixture of additive aggregates. Such matrices can be formed from various materials known in the art, for example: sugars, such as lactose, sucrose or dextrose; polysaccharides, such as maltodextrin or dextrates; starch; cellulose, such as microcrystalline cellulose or microcrystalline cellulose / sodium carboxymethyl cellulose; inorganic substances, such as calcium hydrogen phosphate, hydroxyapatite, tricalcium phosphate, talc or titanium dioxide; and polyols, such as mannitol, xylitol, sorbitol or cyclodextrin.

[0523] Example

[0524] The following examples are provided to illustrate, but not to limit, the present invention.

[0525] Although the present invention is illustrated by the following examples, it should not be construed as being limited thereto; rather, the present invention encompasses the general scope disclosed above. Various modifications and embodiments may be made without departing from its spirit and scope.

[0526] Examples 1-3: Stable oral compositions of celecoxib for investigation

[0527] Compositions containing celecoxib were prepared as shown in Table 1.

[0528] Table 1: Stable oral liquid drug compositions used in the study

[0529] Element Example 1 (% w / w) Example 2 (% w / w) Example 3 (% w / w) Celecoxib 5.00 5.00 4.76 Lauroyl Macrogol Glycerides 4.17 10.00 9.52 Glyceryl Monocaprylate 5.00 5.00 4.76 Tricaprylic / Tricaprin 12.50 12.50 11.90 Polyoxyethylene 35 Castor Oil 25.00 29.50 28.09 PEG-40 Hydrogenated Castor Oil 10.33 0.00 0.00 Sweeteners 8.65 8.65 1.47 Propyl Gallate 0.02 0.02 0.00 Menthol 0.31 0.31 0.18 Flavoring 1.46 1.46 0.32 Ethanol 20.00 20.00 0.00 glycerin 5.21 5.21 0.00 Propylene glycol 0.00 0.00 33.87 Purified water Moderate, up to 100 Moderate, up to 100 Moderate, up to 100

[0530] Preparation steps:

[0531] 1. Add celecoxib to the solubilizers (lauroyl macrogol glycerides, polyoxyl 35 castor oil, and PEG-40 hydrogenated castor oil) and mix thoroughly to obtain a homogeneous mixture.

[0532] 2. Add medium chain glycerides (caprylic / capric triglyceride and caprylic glyceride) to the mixture in step 1.

[0533] 3. Add other ingredients such as flavoring and sweeteners to the mixture from step 2 and mix well.

[0534] 4. Add propylene glycol to the composition of step 3 and mix thoroughly with slight heating at 30°C ± 5°C until a uniform dispersion is obtained and cool the solution to 25-30°C with stirring.

[0535] 5. Add purified water to the composition from step 4 and mix well until a clear solution is obtained.

[0536] 6. Fill the composition of step 5 into an amber glass bottle with an 18 mm child-resistant tamper-resistant cap.

[0537] Example 4: Evaluation of precipitation onset time of stable oral compositions

[0538] The compositions of Examples 1, 2, and 3 were evaluated for the onset of settling time.

[0539] 2 ml of the composition containing 100 mg of celecoxib was added dropwise to 250 ml of FaSSGF at pH 2.0 at 37°C with stirring, and the onset of precipitation was observed.

[0540] Table 2: Time of precipitation onset

[0541]

[0542] Example 5: Evaluation of the dissolution release profile of a stable oral composition

[0543] Celecoxib dissolution studies of 2 ml of the composition of Examples 1, 2 and 3 containing 100 mg of celecoxib were conducted in standard USP dissolution medium under the following conditions: USP Apparatus II paddles; dissolution medium (900 ml 0.01 N HCl containing 0.5% sodium lauryl sulfate), speed of 50 rpm, temperature of 37°C.

[0544] Table 3: Dissolution of stable oral compositions in standard USP dissolution media

[0545]

[0546] Example 6: Evaluation of Physical Properties of Stable Oral Compositions

[0547] We found that the composition of Example 3 was stable after being subjected to stability evaluation conditions of 25°C / 60%RH and 40°C / 75%RH. The composition was also evaluated for viscosity, density, pH, oil droplet size.

[0548] Table 4: Physical evaluation of stable oral compositions

[0549]

[0550] Example 7: Bioavailability of Stable Oral Compositions

[0551] A four-way randomized crossover study was conducted in healthy volunteers under fasting conditions to compare Example 3 (celecoxib oral solution) with 120 mg, 180 mg and 240 mg of the celecoxib oral solution. (Celecoxib) Bioavailability of 400 mg capsules and determination of the dose proportionality of the formulation of Example 3.

[0552] During each study, a single dose of the celecoxib composition was administered orally in the morning after a 10-hour overnight fast. Dosing was accomplished by:

[0553] Treatment-1: The composition of Example 3 containing 120 mg of celecoxib was orally administered to volunteers, followed by drinking about 240 ml of water.

[0554] Treatment-2: The composition of Example 3 containing 180 mg of celecoxib was orally administered to volunteers, followed by drinking about 240 ml of water.

[0555] Treatment-3: The composition of Example 3 containing 240 mg of celecoxib was orally administered to volunteers, followed by drinking about 240 ml of water.

[0556] Treatment-4: 400 mg oral dose (1x400 mg) The capsules are administered with approximately 240 ml of water.

[0557] result:

[0558] Celecoxib plasma concentrations and other pharmacokinetic parameters were determined. The observed pharmacokinetic parameters are given in Table 5.

[0559] Table 5: Pharmacokinetic parameters after administration of stable oral compositions a Median (range)

[0560]

[0561] Example 8: Study on the use of stable oral compositions for the treatment of migraine

[0562] A three-way double-blind randomized crossover trial was designed to determine the efficacy of Example 3 (celecoxib oral solution) at doses of 120 mg and 240 mg compared to placebo in the treatment of migraine. 60 individuals with a 2-6 year history of episodic migraine were recruited.

[0563] During each study, a single dose of the celecoxib composition was administered orally in the morning after a 10-hour overnight fast. Administration was accomplished by:

[0564] Treatment-1: The composition of Example 3 containing 120 mg of celecoxib was orally administered to volunteers, followed by drinking about 240 ml of water.

[0565] Treatment-2: The composition of Example 3 containing 240 mg of celecoxib was orally administered to volunteers, followed by drinking about 240 ml of water.

[0566] Treatment-3: Subjects were orally administered placebo followed by drinking 240 ml of water.

[0567] Subjects were monitored for pain at 2 hours and 24 hours post-dose and for the most bothersome symptom (MBS) at 2 hours post-dose.

[0568] During each migraine attack, trial medication was used once at the onset of a moderate to severe migraine (defined as a patient headache rating of 2 or 3 on a scale of 0 to 3), but no later than 1 hour after the onset of a moderate migraine.

[0569] Patients were asked to rate the severity of their headaches on a scale of 0 (no pain) to 3 (severe pain), which is the recommended method for obtaining patient ratings of headaches (reference: Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators" Tfelt-Hansen P, Pascual J, Ramadan N et al., Cephalalgia, 2012; 32(1): 6-38).

[0570] Ratings were obtained immediately before ingestion of the test drug (time 0) and 10, 15, 20 and 30 minutes and 1, 2, 1.5, 2, 24 and 48 hours after administration. During the study, patients recorded the rating of each migraine treated in an electronic diary (eDiary). The severity rating scale was also used to assess the recurrence of headaches after headaches were eliminated during the 24 hours after administration. The record also includes any recurrence of headaches after headaches were eliminated using the headache severity rating scale during the 24 hours after the use of the test drug; symptoms (nausea, photophobia and phonophobia); rescue medication use (date, time); functional impairment; and patient satisfaction (before the use of rescue medication).

[0571] The results of the above clinical studies show that Figure 4 , Figure 5 , Figure 6 , Figure 7 and Table 6 and Table 7.

[0572] Table 6: Primary efficacy analysis of headache elimination: ITT population, observed cases, and overall treatment period

[0573]

[0574] Abbreviation: ITT = intention to treat

[0575] Note: The response rate (%) was calculated as the number of patients who responded at a given time point divided by the number of patients with no missed assessments at that time point.

[0576] Note: P values ​​are from McNemar's test for independent pairs. '-' indicates that the test could not be performed due to missing paired data. When there are less than 20 discordant pairs, the exact test should be applied.

[0577] Table 7: Secondary efficacy analysis for the most bothersome symptom: ITT population, last observation carried forward

[0578]

[0579] Abbreviation: ITT = intention to treat

[0580] Note: The response rate (%) was calculated as the number of patients who responded at a given time point divided by the number of patients with no missed assessments at that time point.

[0581] Note: P values ​​are from McNemar's test for independent pairs. '-' indicates that the test could not be performed due to missing paired data. When there are less than 20 discordant pairs, the exact test should be applied.

[0582] In at least some of the aforementioned embodiments, one or more elements used in the embodiments may be used interchangeably in another embodiment, unless such replacement is technically infeasible. It will be appreciated by those skilled in the art that various other omissions, additions and modifications may be made to the above methods and structures without departing from the scope of the claimed subject matter. All of these modifications and variations are intended to fall within the scope of the subject matter defined by the appended claims.

[0583] For the use of substantially any plural and / or singular terms, those skilled in the art may translate from the plural to the singular and / or from the singular to the plural, as appropriate to the context and / or application. For clarity, various singular / plural arrangements may be expressly set forth herein.

[0584] Those skilled in the art will appreciate that, in general, the terms used herein, and particularly in the appended claims (e.g., the bodies of the appended claims), are generally intended to be "open" terms (e.g., the term "including" should be interpreted as "including but not limited to," the term "having" should be interpreted as "having at least," etc.). Those skilled in the art will also appreciate that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly stated in the claim, and in the absence of such a statement, such an intent is absent. For example, to aid understanding, the following appended claims may contain the use of the introductory phrases "at least one" and "one or more" to introduce claim recitations. However, the use of these phrases should not be interpreted as implying that the introduction of a claim recitation by the indefinite article "a" or "an" limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases "one or more" or "at least one," and an indefinite article such as "a" or "an" (e.g., "a" and / or "an" should be interpreted as "at least one" or "one or more"); the same is true for the use of definite articles used to introduce claim recitations. In addition, even if a specific number of introduced claim expressions is explicitly stated, one skilled in the art will recognize that such statement should be interpreted to mean at least the cited number (e.g., merely stating "two expressions" without other modifiers means at least two expressions, or two or more expressions). Furthermore, where a convention similar to “at least one of A, B, and C, etc.” is used, such syntactic construction is generally considered in the sense of the convention as understood by those skilled in the art (e.g., “a system having at least one of A, B, and C” includes, but is not limited to, systems having only A, only B, only C, A and B, A and C, B and C, and / or A, B, and C, etc.). Where a convention similar to “at least one of A, B, or C, etc.” is used, such syntactic construction is generally considered in the sense of the convention as understood by those skilled in the art (e.g., “a system having at least one of A, B, or C” includes, but is not limited to, systems having only A, only B, only C, A and B, A and C, B and C, and / or A, B, and C, etc.). Those skilled in the art will also understand that virtually any disjunctive word and / or phrase presenting two or more alternative terms, whether in the specification, claims, or drawings, should be understood to contemplate including one of the terms, either or both of the terms. For example, the phrase “A or B” would be understood to include the possibility of “A” or “B” or “A and B”.

[0585] In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.

[0586] It will be understood by those skilled in the art that for any and all purposes, for example, in terms of providing a written description, all ranges disclosed herein also encompass any and all possible sub-ranges and combinations of sub-ranges thereof. Any listed range can be easily considered to be fully described and to allow the range to be decomposed into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range discussed herein can be easily decomposed into a lower third, a middle third, and an upper third, etc. It will also be understood by those skilled in the art that all languages, such as "up to", "at least", "greater than", "less than", etc., include the numbers described, and refer to ranges that can be subsequently decomposed into sub-ranges as described above. Finally, it will be understood by those skilled in the art that ranges include each individual individual. Therefore, for example, a group having 1-3 items refers to a group having 1, 2, or 3 items. Similarly, a group having 1-5 items refers to a group having 1, 2, 3, 4, or 5 items, and so on.

Claims

1. Use of celecoxib in the preparation of a medicament in the form of a stable oral liquid pharmaceutical composition for providing pain relief to a human subject suffering from pain, the composition comprising celecoxib in an amount of about 120 mg to about 240 mg, at least one medium chain glyceride, at least one polar solvent, at least one solubilizing agent and at least one pharmaceutically acceptable excipient, The amount of celecoxib is 1% to 8% by weight of the total weight of the composition. wherein the average oil droplet size of the composition is no greater than 500 nm when tested in 250 ml of fasting state simulated gastric fluid (FaSSGF) at pH 2.0 and 37°C ± 0.5°C under stirring at a speed of 50 rpm, and wherein the medicament is for administration to the subject to provide pain relief 2 hours after administration, wherein the medicament provides at least one of the following pharmacokinetic parameters when orally administered to a human subject under fasting conditions: a. AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ; b. AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ; c. AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ; d. AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ; e. AUC of at least about 2000 ng.h / mL (0-t) ; f. AUC of at least about 2000 ng.h / mL (0-∞) ;as well as g. T not exceeding 8 minutes lag .

2. The use according to claim 1, wherein the pain relief is maintained for at least about 2 hours to about 24 hours.

3. Use of celecoxib in the preparation of a medicament in the form of a stable oral liquid pharmaceutical composition for providing partial pain relief to a human subject suffering from pain, the composition comprising celecoxib in an amount of about 120 mg to about 240 mg, at least one medium chain glyceride, at least one polar solvent, at least one solubilizing agent and at least one pharmaceutically acceptable excipient, wherein the average oil droplet size of the composition is no greater than 500 nm when tested in 250 ml of fasting state simulated gastric fluid (FaSSGF) at pH 2.0 and 37°C ± 0.5°C under stirring at a speed of 50 rpm, and wherein the medicament is for administration to the subject to provide partial pain relief in less than about 2 hours after administration, wherein the medicament provides at least one of the following pharmacokinetic parameters when orally administered to a human subject under fasting conditions: a. AUC of about 10 ng.h / mL to about 80 ng.h / mL (0-15min) ; b. AUC of about 80 ng.h / mL to about 400 ng.h / mL (0-30min) ; c. AUC of about 400 ng.h / mL to about 1500 ng.h / mL (0-1hr) ; d. AUC of about 1000 ng.h / mL to about 4000 ng.h / mL (0-2hr) ; e. AUC of at least about 2000 ng.h / mL (0-t) ; f. AUC of at least about 2000 ng.h / mL (0-∞) ;as well as g. T not exceeding 8 minutes lag .

4. The use according to claim 1 or 3, wherein the pain is acute pain, chronic pain, visceral pain, surgical pain, bone injury pain, inflammatory pain or any breakthrough pain.

5. The use according to claim 3, wherein the partial pain relief is that the pain intensity reported by the human subject suffering from pain is at least ≥ 1 level lower than the rating before administration according to a numerical rating scale for pain ranging from 0 (no pain) to 3 (severe pain).

6. The use according to claim 3, wherein the partial pain relief is maintained for at least about 4 hours.

7. The use according to claim 1 or 3, wherein the amount of the polar solvent is from 20% to 80% by weight of the total weight of the composition.

8. The use according to claim 1 or 3, wherein the amount of the solubilizer is from 10% to 70% by weight of the total weight of the composition.

9. The use according to claim 1 or 3, wherein the amount of the medium chain glycerides is 5 to 75 wt% of the total weight of the composition.

10. The use according to claim 1, wherein the composition provides pain relief in at least 25% of the treated human subjects at 2 hours.

11. The use according to claim 1 or 3, wherein the AUC of the composition is (0-15min) It is at least 50 times higher than the conventional celecoxib 400 mg oral capsule.

12. The use according to claim 1 or 3, wherein the AUC of the composition is (0-30min) It is at least 12 times higher than the regular celecoxib 400 mg oral capsule.

13. The use according to claim 1 or 3, wherein the AUC of the composition is (0-1hr) It is at least 5 times higher than the regular celecoxib 400 mg oral capsule.

14. The method according to claim 4, wherein the pain is migraine, cluster headache, neuropathic pain, postoperative pain, herpetic neuralgia, phantom limb pain, central pain, dental pain, opioid-resistant pain, pain during labor and delivery, pain caused by burns, sunburn pain, postpartum pain, angina pectoris, pain related to the genitourinary tract, cystitis pain, arthritis pain, ankylosing spondylitis pain, primary dysmenorrhea pain or any type of cancer pain.

15. The use according to claim 4, wherein the pain is osteoarthritis pain or juvenile rheumatoid arthritis pain.

16. The use according to claim 1 or 3, wherein the composition does not show any precipitation in fasting state simulated gastric fluid (FaSSGF) at pH 2.0 and temperature 37°C ± 0.5°C when measured at 60 minutes under stirring at a speed of 50 rpm.

Citation Information

Patent Citations

  • Substituted pyrazolyl benzenesulfonamides

    US5466823A

  • Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation

    US5760068A